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Abstract 
 
HIV pathogenesis relies on infection of CD4+ cells. Viral entry into these cells initially 
utilizes CCR5 to infect monocytes and macrophages, and may later use CXCR4 to infect 
T cells. Later stage HIV infection progressing towards AIDS is characterized by high 
viral load and CD4+ T cell depletion. In HIV-1 subtype C infections, there is rarely a 
switch to CXCR4. However, T cells, which are predomoninantly CXCR4+ cells, still 
decrease in number. To shed some light on the cause of T cell depletion, HIV-gag 
specific FISH and HIV V3 loop sequencing were used to assert the location of the virus, 
and the chemokine coreceptor used, respectively. The majority of CD4+ cells in blood 
and bone marrow extracts of late stage HIV+ patients possessed positive signals. T cells 
were present in large number compared to monocytes/ macrophages in both 
compartments. Sequencing indicated CCR5 was still the preferred chemokine coreceptor. 
These findings support the hypothesis that the virus is able to enter T cells, despite a lack 
of coreceptor switching. It also raises the questions of whether CCR5 is upregulated on T 
cells, or other mechanisms are used by the virus to gain entry into T cells. 
 
 xiv
Chapter 1: Introduction 
 
1.1 General background 
 
Acquired Immune Deficiency Syndrome (AIDS) was first recognized in 1982 as a 
communicable disease that can be transmitted via sexual contacts, intravenous drug use, 
and blood transfusion (Barre-Sinoussi et al, 1983). However, its causative agent, the 
Human Immunodeficiency Virus (HIV) was only determined in 1983/4 to be a retrovirus 
that targets the helper/inducer T cells (Barre-Sinoussi et al., 1983; Gallo et al., 1984; 
Sarngaharan et al., 1984), much like the two other exogenous retroviruses that target 
humans, characterized since 1980 (Feinberg et al., 1986). Consequently, the virus was 
initially named Human T Lymphotropic Virus (HTLV) –III, as it was thought to have 
close association with the other two HTLV species. Although this has been shown to be 
the case - immunological and nucleic acid data had revealed HIV does belong to the 
HTLV family, and have closer association to HTLV-II than –I (Schupbach et al, 1984; 
Sarngadharan et al., 1984) – the etiology of HIV is very different to the other two HTLV 
members. HTLV-I has been implicated as the cause of adult T cell leukemia as well as 
HTLV-I-associated myelopathy/tropical spastic pararesis (HAM/TSP) (Barmak et al., 
2003); HTLV-II is associated with a T-cell variant of hairy cell leukemia (Kalyanaraman 
et al., 1982). Both of these viruses have been found in AIDS patients as well, suggesting 
some possible etiological links between the three HTLV species.  
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Aside being known as HTLV-III, HIV also went by the names lymphadenopathy virus 
(LAV) and AIDS-associated retrovirus (ARV). As researchers revealed more of the 
virus’ characteristics, it became more obvious that it shares a number of similarities with 
members of the nontransforming cytopathic lentivirus family of the retroviruses (Barre-
Sinoussi et al., 1983). This is where scientists have placed it at present. With respect to 
the other members of the lentiviruses (e.g. sheep visna virus, equine infectious anemia 
virus, feline immunodeficiency virus), HIV possesses similar morphological, biological, 
molecular and pathogenic characteristics. Perhaps the closest member to the HIV is the 
primate variation of the virus, called Simian Immunodeficiency Virus (SIV). There are 
multiple SIV variants, originating from different species. HIV-1 is most closely related to 
the virus found in chimpanzees (SIVCPZ), which suggest cross-species transmission from 
the chimpanzee. But SIV-positive chimpanzees have rarely been documented, making it 
difficult to determine the pathogenesis of SIVCPZ. However, SIV-positive chimpanzees do 
not seem to suffer from the same deleterious effects as HIV-infected humans, which 
suggest that SIVCPZ may itself have been the product of another cross-species 
transmission (Sharp et al., 1999).  
 
 Another retrovirus was also found in West African AIDS patients in 1986 and was 
determined to have similar biological and morphological properties to HIV-1; it was 
subsequently named HTLV-IV, or HIV-2. However, while the envelope glycoproteins of 
HIV-2 differ greatly to HIV-1, there is a serological commonality between HIV-2 and 
SIV. This suggests that HIV-2 is more closely related to the simian virus than HIV-1 
(Clavel et al., 1986), and have led to the hypothesis that HIV-2 infection is a zoonosis, a 
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process whereby a disease of animal is transmitted to man and becomes established in 
human population. The zoonosis theory for the rise of HIV-2 has been generally accepted 
as a valid one, due to the amount of genetic evidence linking it to the primate form of the 
virus. It remains uncertain how HIV-1 appeared and adapted itself to human. HIV-2 
infected individuals do exhibit clinical syndromes very similar to those infected with 
HIV-1 (Clavel et al., 1987), but the rate of death is much lower than compared to HIV-1 
positive individuals (Poulsen et al., 1997). Early studies of HIV-2 had also suggested that 
co-infection of HIV-1 and HIV-2 can slow down the progression of the more aggressive 
HIV-1, but that been shown not to be the case with a more recent study that had a larger 
cohort (Schim van der Loeff et al., 2001).  
 
HIV-1 has a number of genetic strains, classified into three clades, M (main), O (other), 
and N (non-M, non-O). Within these classifications, there are also divisions of subtypes 
as well as variants created from two or more existing subtypes, called circulating 
recombination forms (CRFs). HIV subtypes are defined as having genomes that are at 
least 25% unique. Eleven subtypes and thirteen CRFs have been identified so far, and 
almost all subtypes and a number of CRFs can be found in Africa. Naturally, most of the 
HIV subtypes are within the M clade, and HIV-1 subtype C is the most prevalent strain of 
the virus at present. It contributes to approximately 50% of the new infections worldwide, 
although it is most commonly found in Africa and parts of Asia. It usually spreads via 
heterosexual contacts. The second most prevalent strain is subtype A, which accounts for 
the 30% of new infections, while the most common subtype found in America and 
Europe Australia is subtype B, which seems to spread by homosexual contacts or 
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intravenous drug users (Berkelman et al., 1989; Quinn, 1990). According to UNAids’s 
2004 report, there are a total of 39 million people infected with HIV at the end of 2003, 
of which of which 4.9 million were new infections; at the same time 3.1 million had died 
from AIDS and associated diseases (http://www.unaids.org). While this seems to be a 
small decrease, compared to the 2003 figure (40 million infected, 3 million deaths) it is 
not indicative of the decline of the pandemic. Rather, it may be in indication of the 
infection rate hitting a plateau, while death rate are starting to increase as more and more 
infected individuals reach AIDS.  
 
The most badly affected region by HIV-1 at the present is Sub-Saharan Africa, where it 
accounts for approximately 65% of all of the three figures quoted above. But more 
specifically, it is southern Africa that is worst hit, and most countries in the region are on 
top of the list of the world’s highest HIV-infected populations. Botswana and Swaziland 
tops the list, with around 38% of adults (15-49 years old) infected with HIV, followed by 
Lesotho, Zimbabwe, South Africa, and Namibia (http://www.unaids.org). It should be 
stated, however, that percentage of population affected is somewhat misleading, as it 
does not reflect the absolute number of infected individuals, and therefore does not mean 
these countries has the highest total number of HIV/AIDS cases. Indeed, when compared 
with the highly populous Asian countries, where 1% prevalence may means 10 million 
people are infected with the virus, as opposed to 38.8% prevalence equating 220 000 
people in Swaziland. Having said that, data shows that South Africa presently has the 
most number of documented HIV+ cases, which is approximately 5 million individuals. 
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Therefore it should be kept in mind that while the various numbers represent one facet of 
the HIV problem, it should not be seen as the complete picture to the HIV epidemic.  
 
Beyond the genetic classifications, the virus is further divided by the mechanism of their 
entry into the host cells. Almost all HIV infections begin using the chemokine receptor 
CCR5 and are hence termed R5-using viruses (Schuitemaker et al., 1992; van’t Wout et 
al., 1994). Later in the infection, some virus, particularly those of the subtype B strain, 
have the tendency to switch chemokine receptor usage from CCR5 to CXCR4, or use 
both receptors at the same time. These variants are termed X4-using (or R5X4) viruses, 
and are much more virulent, as well as being able to induce the formation of large, 
multinucleated cells in vitro, otherwise known as synctia formation (Bjorndal et al., 1997; 
Tscherning et al., 1998). This ability to induce synctia formation has also led to alternate 
names for the virus. The R5-using virus is considered to have a non-syncytium inducing 
phenotype, while the X4-using virus has a syncytium-inducing phenotype. A third class 
of differentiation between the two groups looks at their growth rate in vitro: The non-
syncytium-inducing/R5-using virus has a slow/low (S/L) rate of growth, while the 
syncytium-inducing/X4-using virus has a rapid/high (R/H) growth rate (Asjo et al., 1986).  
 
X4-using viruses has been shown to be more virulent due to their ability to cause synctia 
in vitro, and is a strong indicator of decline in CD4 cell count and disease progression 
(Koot et al., 1993; Shafer, Aguiniga & Merigan, 1995). It does not, however, increase the 
immediate risk of death (Richman & Bozzette, 1994). Furthermore, the X4-using virus 
very rarely causes synctia in vivo, which leads to question as to why and how it is more 
 5
virulent in the infected system. This accelerated disease progression could be due to the 
use of additional chemokine coreceptor that has allow infection of previously 
unassailable cells (CD4+ T cells), and cause the immune system to deteriorate even faster. 
 
 
Figure 1.1: Progression of HIV infection towards AIDS, with specific reference to 
the important events that are markers in pathogenesis and clinical status of the 
infected individual (From Pantaleo et al., 1993). The numbers present on both axes 
are general values, as the progression of the disease can vary from individuals.  
 
The mutations may also enhance the binding affinity of gp120 when interacting with 
CXCR4 when compared to CCR5, which increase the efficiency of entry by the virus into 
cells. This change in receptor usage occurs due to mutations that appear in the third 
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hypervariable loop of gp120, and has been associated with the phenotypic change in 
subtype B (De jong et al., 1992; Shizimu et al., 1999).  
 
The clinical progression of HIV infection towards AIDS has been clearly documented by 
research studies and reviews (Morrow, Park & Wakefield, 1994; Pantaleo, Grazlosi & 
Fauci., 1993). Clinically, the progression can be put into two broad categories: acute and 
chronic phase. After a primary infection, 40 to 90 percent of infected individuals present 
an acute mononucleosis-like or flu-like syndrome 3 to 6 weeks after the initial infection. 
Symptoms include fever, malaise, maculopapular rash, and oral ulcers, to name a few. 
Due to the similarity of symptoms between viral-based flu and the initial HIV infection, 
and the fact that there is no detectable HIV-1 antibody at this point, it is next to 
impossible to determine if an HIV infection has occurred, unless there are circumstantial 
evidences alluding to the possibility of HIV infection. A high level of viraemia is also 
present at this time, accompanied by body-wide dissemination of the virus. This leads to 
an immune response against the virus within a week to three months of the first physical 
symptoms, which is the point where seroconversion takes place – that is, the presence of 
anti-p24 and anti-160gp antibodies is detected in the body. The HIV-1-specific antibodies 
also bring about a rapid decline of detectable viraemia in the body, although that doesn’t 
seem to stop the viral replication fully (Morrow, Park & Wakefield, 1994; Pantaleo, 
Grazlosi & Fauci., 1993).  
 
Once seroconversion occurs, there is still a latent stage of variable time period where 
there are few clinical symptoms, except the slow increase of viral load and decrease in 
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CD4+ T cells in the blood. The chronic phase of the disease reaches its end when the CD4 
count of the infected individual declines to two hundred or less per microlitre of blood. 
This is classified as full-blown AIDS, at which point, the individual becomes very 
susceptible to opportunistic infections like tuberculosis. Other common diseases that 
affect AIDS patients include thrush, Kaposi sarcoma, Pneumocystis carinii Pneumonia 
(PCP), Non-Hodgkin Lymphoma (NHL), cryptococcal meningitis, and mycobacterium 
avium. At this late stage, the virus can also be found in the central nervous system, 
leading to peripheral neuropathy, or dementia and other neurological disorders in more 
severe cases.  Therefore, HIV infection does not directly cause death, but weakens the 
immune system sufficiently so that when opportunistic diseases invade the body, the 
pathogen overwhelms the body and cause death. Figure 1.1 describes the progression of 
the infection with respect to the viraemia and CD4+ T cell counts, with reference to 
certain key events, described above (Morrow, Park & Wakefield, 1994; Pantaleo, 
Grazlosi & Fauci., 1993).  
 
 
1.2 Genetic and structural makeup of HIV 
 
HIV has a ~10kb proviral genome, encoding for fifteen proteins and enzymes. While not 
all of these are essential for the proliferation of the virus, the less important gene products 
do aid in a more efficient process thereof. The genome is flanked on both sides by long 
terminal repeats (LTR) that are identical to one another and regulate both HIV replication 
and viral expression. The latter function of LTR affects the three major viral genes: the 
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gag (group-specific antigen) gene that encodes for the structural proteins, pol (protease, 
reverse transcriptase, and integrase) gene that produce the enzyme complex reverse 
transcriptase-protease-endonuclease, and the env (envelope) gene that give rise to both 
the internal and external glycoprotein envelope (Morrow, Park & Wakefield, 1994).  
 
1.2.1 The major viral genes 
The gag gene produces a polyprotein precursor (Pr55gag) which undergoes proteolytic 
cleavage to produce the matrix protein, the capsid protein, and the nucleocapsid protein. 
The matrix protein is a 17kDa molecule that associates itself with the inner surface of the 
viral membrane as well as the icosahedral capsid of the core. It has also been suggested 
that the matrix protein is required to incorporate the envelope proteins into mature virions, 
and aid in virus entry. The 24kDa capsid protein was produced from the central domain 
of Pr55gag and creates the shell of the cone-shaped core of the virus that houses the 
genomic viral RNA and enzymes; it also contains motifs needed for proper viral 
assembly. The carboxy terminus of the gag polyprotein also seems to have functions in 
assembly, as well as producing the nucleocapsid proteins. The nucleocapsid is a 9-kDa 
protein that associates with viral RNA in the virion core; it also has a role in virion 
assembly. A small proline-rich peptide (p6) is produced from the carboxy terminus of the 
gag polyprotein, and affects the efficiency of virion budding on the cell surface. There are 
also other small peptides (e.g. p9) that are produced from the terminus, but these have not 
been found with a function at present (Morrow, Park & Wakefield, 1994).  
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 Figure 1.2: Organization of HIV genome. The approximately 10kb RNA sequence is 
flanked by Long Terminal Repeats (LTRs), and genes for the necessary proteins 
and enzymes are situated between them. 
(Taken from http://uhavax.hartford.edu/bugl/hiv.thtm).  
 
The pol gene is responsible for the three viral enzymes, and they are produced as a 
polyprotein, much like the gag polyprotein. The initiation site and 200-odd nucleotides of 
the 5’-end of pol overlaps with the 3’-end of gag, and the production of the pol 
polyprotein requires ribosomal frameshifting (the ribosome slipping back by 1 base) in 
order to create the correct codons. The 160 kDa pol precursor polyprotein is therefore a 
fusion protein created from both the gag and pol genes.  The HIV protease is the first to 
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be produced from the polyprotein by autoprocessing event, and it needs to be fully active 
before the other two enzymes can be produced – it is responsible for the cleaving events 
on the pol polyprotein to release the reverse transcriptase and integrase.  
 
The gag precursor polyprotein also requires the protease’s activity to be processed. 
Considering its compulsory presence in a number of early protein formations, it is 
perhaps not surprising mutations in the protease can cause the production of 
noninfectious HIV virions. The reverse transcriptase (RT) is a dimeric enzyme, initially 
composed of two identical 66kDa (p66) polypeptides. The homodimer then undergo 
asymmetric endoproteolytic cleavage, where the one subunit is reduced to a 51 kDa (p51) 
polypeptide. Although the p51 subunit has demonstrated no enzymatic activities, its 
removal terminates certain activities on the other subunit. The viral RT has a number of 
catalytic activities, including DNA polymerase activity that copy both DNA and RNA 
templates and ribonuclease H activity, which degrades RNA in a RNA-DNA hybrid 
duplex. The HIV integrase is a 32 kDa protein and is essential for the integration of 
retroviral DNA into the host genome. It also possesses a number of functions, including 
DNA binding, specific DNA endonuclease activity, DNA integration and recombination 
(Morrow, Park & Wakefield, 1994).  
 
The env gene produces yet another polyprotein precursor, which give rise to two mature 
form of envelope glycoprotein. The precursor is an 88 kDa polypeptide that is cleaved 
during translocation to the rough endoplasmic reticulum, where glycosylation and folding 
occurs. It then undergoes oligomerization to give stability to the protein. The 
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glycosylated precursor is now 160kDa (gp160), and is cleaved in the Golgi to produce a 
120kDa surface glycoprotein, and a 41kDa transmembrane glycoprotein. These are 
transported to the plasma membrane to be incorporated into the budding virions. This 
process is quite inefficient, as only 5-15% of the gp160 precursors are cleaved to produce 
the two glycoproteins. The two envelope proteins are noncovalently linked to one another 
as trimers, present as spikes on the viral membrane; the strength of the association varies 
between strains. Both proteins are essential for the viral infection to occur, and this will 
be looked at in more detail (Morrow, Park & Wakefield, 1994).  
 
1.2.2 The accessory genes 
Six other genes exist in the proviral genome as well, and produce what can be classified 
as accessory or auxiliary proteins. They all possess regulatory functions and are able to 
influence the pathogenesis of the virus. Initially, most of these were thought to be 
noncompulsory proteins, and was merely there to enhance or aid the viral infection, but 
studies have determined that these proteins are just as important, if not essential, to the 
virus’ life-cycle. The trans-acting transcriptional activator (tat) gene is among the first 
genes to be expressed and produce the most important of the accessory proteins. Tat’s 
principle function is to bind to the tat activation response (TAR) element on the 5’ end of 
the nascent mRNA and recruits cellular factors that promote processivity of transcription 
from the viral long terminal repeats (LTRs) (Turner and Summer, 1999). However, the 
mechanism of interaction is not fully elucidated between the tat and TAR element, and 
there have been indications that tat can still bring about transcription in the absence of 
TAR (Morrow, Park & Wakefield, 1994).  
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Tat has been singled out as the viral protein that seems to cause the majority of changes 
in the physiological behaviours of cells in the infected system. These include the 
upregulation of CXCR4 expression on erythroid cells (Gibellini et al., 2003), 
upregulation of inflammatory mediators and induction of monocytes into the brain (Pu et 
al., 2003), to name a few. It is unknown why tat protein is able to influence so many 
mechanisms outside the virus, although its presence throughout the body can certainly be 
attributed to the fact it is a soluble protein, and thus able to move into any area by 
following the movement of bodily fluids.  
 
 The trs or rev (regulator of virion expression) protein is required for viral replication, 
and is involved in the controlling the movement of RNA between the nucleus and 
cytoplasm. Rev binds the rev response element (RRE) on nascent unspliced mRNA, 
which recruits nuclear shuttling proteins to export the molecule and then import the 
processed mRNA. The rev protein is thus able to induce cytoplasmic expression of highly 
spliced mRNA (tat, rev, and nef) in early synthesis, and later, the unspliced genomic 
mRNA (gag and gag-pol) and singly spliced mRNAs (env, vpu, vif and vpr) mRNAs. It 
is also able to upregulate HIV synthesis via a trans-acting anti-repression mechanism 
(Feinberg et al., 1996), as well as reduces expression of doubly spliced RNA encoding 
for the viral regulatory proteins.   
 
Two of the virus’ regulatory/accessory proteins, Vpu (viral protein U) and Nef (negative 
factor), downregulate the surface expression of the CD4; they also have a similar but 
lesser effect on the expression of the major histocompatibility complex I. Vpu associates 
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itself with CD4 in the endoplasmic reticulum and recruits it to undergo proteolysis, 
whereas the Nef protein mediates endocytosis on removing the CD4 already on the cell 
surface (Emerman & Malim, 1998). However, recent data seems to indicate the function 
of Nef is more poised toward enhancing HIV-1 pathogenicity in vivo (Stoddart et al., 
2003), even though it seem have been shown to be nonessential to viral replication in 
vitro (Herbein et al., 1998). While the reason for the virus to target CD4 for removal 
remains unclear, it is possible that these are mechanisms to both enhance infection as 
well as avoiding immune surveillance. Within the cells, CD4 and the envelope protein are 
both produced in the endoplasmic reticulum, and the removal of vpu can prevent 
premature binding of env. The downregulation of CD4 receptor expression would also 
prevent reinfection of the cell by budding virions (Turner & Summers, 1999).  
 
The R or Vpr (viral protein R) gene as it has come to be known as, produces a protein that 
cause the nuclear localization of the preintegration complex (PIC), containing integrase, 
matrix, reverse transcriptase, and Vpr in early synthesis. Vpr also have the ability to 
delay host cells for extended periods of time in theG2 phase, thus providing sufficient 
time for the virus to replicate (Emerman & Malim, 1998). The last accessory protein, Vif 
(viral infectivity factor) protein seemed to have strong effects in the infectivity of the 
virus in vitro, as its absence leads to the virus being 1500-2000-fold less infectious, and 
only allows the infection of transformed T cell lines in vitro (Mariani et al., 2003).  
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1.3 Mechanism of HIV-1 infection 
 
HIV requires three components for successful invasion of the host cells. The first is its 
own envelope glycoprotein, gp120. The other two are the CD4 receptor and the 
chemokine receptor on the host cell. As previously stated, the envelope glycoprotein are 
made up of the gp120 surface protein and the gp41 transmembrane protein, which are 
non-covalently bonded to one another one the viral membrane as trimers (Cilliers & 
Morris, 2002). Gp120 has 5 conserved regions (C1-C5) that makes up its core, as well as 
5 variable loops (V1-V5); it contain binding sites for both CD4 and the chemokine 
receptors. Gp41 possess 3 domains, one of which interact with the matrix protein, the 
second is the transmembrane domain, and lastly the external ectodomain (Morrow et al., 
1994). CD4 is a 50kDa membrane glycoprotein that acts as a transducer in activation of 
peripheral T cells and differentiation of thymocytes. It is expressed on the surface of T 
cells, monocytes, dendritic cells and microglia in the brain. It primary function is in MHC 
II restricted interactions in immune responses, where T helper cells interact with antigen 
presenting cells (APCs) like dendritic cells to mount an immune response against the 
target antigen (MeSH database, 2004). Chemokine receptors are members of the seven-
transmembrane domain receptor superfamily.  
 
1.3.1 Chemokine receptor and HIV 
The chemokine coreceptor is the most varied out of the three components. These 
receptors are members of the seven-transmembrane domain receptor superfamily. They 
are also known as G-protein coupled receptors, as the intracellular signals they transmit 
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are done so via the dissociation of heterotrimeric GTP-binding proteins. The receptors are 
340-370 amino acids in length and positioned across the bilipid membrane, where the 
amino-terminal and three loops are presented extracellularly. The classification of 
chemokine receptors are closely modeled on the chemokine/s they interact with. All the 
chemokines have a conserved cysteine-based motif near their amino-termini, and differs 
in the number and sequential arrangement of the cysteine. Known classes of chemokine 
at this point include CXC, CC, C, and CX3C, where the receptors for the first two classes 
(CXCR, CCR) are most relevant to HIV infection (Martin-Garcia et al., 2002). 
 
Although CD4 was identified as the primary receptor fairly early on, it was found that the 
receptor only supported viral entry on a human cell. This suggested that a second, 
species-specific coreceptor was required to allow viral entry. It was proven to be correct 
when an orphan G-coupled receptor, fusin, was found to allow HIV-1 infection when 
coexpressed with CD4 (Feng et al., 1996). The discovery was quickly followed by the 
identification of CC-CKR-5, an alternative coreceptor that allows infection by the 
macrophage-tropic strain, as opposed to fusin which allowed infection by the T-cell 
tropic strain (Deng et al., 1996; Dragic et al., 1996). The two receptors were later 
renamed to CXCR4 and CCR5, respectively, to reflect their functionality. To this date, 
CXCR4 is only know to bind the chemokine SDF-1 (stromal derived factor-1), whereas 
CCR5 have a number of ligands, including MIP (macrophage inflammatory protein) -1α 
and -1β, as well as RANTES (regulated upon activation, normal T cell expressed and 
secreted) (Alkhatib et al., 1996).  
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It is important to look at the chemokine receptors in some details, as they are the 
components that can provide some natural resistance against viral entry. The first 
indication of possible HIV-1 resistance was when some highly exposed, but uninfected 
Caucasians were found. It was determined that a 32bp deletion on the CCR5 gene 
(CCR5∆32) led to the production of a truncated protein, which fails to present itself on 
the cell surface. This mutation is somewhat common in those of Caucasian descent (15-
20% of population is heterozygous; 1% homozygous mutant), but is rare in other 
populations (Liu et al., 1996; Samson et al., 1996). The heterozygous individuals have a 
decreased likelihood of infection by the R5 virus, and it is almost impossible for those 
with homozygous mutant to be infected. However, this protection only extends to the R5 
virus, and these individuals can still be infected by dual-tropic, or X4 viruses. This was 
demonstrated sufficiently well by cases of CCR5∆32 homozygous individuals being 
infected by X4 virus, with exclusive and persistent CXCR4 usage (O’Brien et al., 1997; 
Theodorou et al., 1997). While the average number of CCR5 receptor on any given 
macrophage has yet to be quantified, it has been shown that a high number of CCR5 can 
better facilitate the entry of the virus, and also determine the virus’ postentry efficiency 
(Reynes et al., 2001; Lin et al., 2002).   
 
It is unknown what controls the degree of expression of CCR5 on cell surface, but it 
would be of great interest to determine the mechanism, and perhaps suppress CCR5 
expression. This should theoretically have little effects on the cells in vivo, as CCR5 is a 
redundant receptor – its ligands, MIP-1α, -1β and RANTES are able to utilize other 
chemokine receptors. Perhaps the most convincing evidence is that homozygous 
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CCR5∆32 individuals seem to suffer from no ill-effects from the absence of the receptor 
(Liu et al., 1996). The influence of chemokines as competitive inhibitors against viral 
binding has also been looked at in CCR5 and its ligands. It was found that RANTES was 
the most potent inhibitor, followed by MIP-1α and -1β. The presence of these chemokine 
in vivo seldom approach the high concentration required to fully inhibit viral interaction 
with the receptor, but they are able to provide some deterrence to the process (Alkhatib et 
al., 1996).  
 
There are also other less influential polymorphisms on CCR5 that have been found to 
affect viral infection or transmission. These include the CCR5P1 allele that enhance 
AIDS progression (Martin et al., 1998), CCR5-59353C that slows CD4 decline, and 
CCR5-59356T that increase perinatal transmission (Kostrikis et al., 1999), to name a few. 
While there are no mutations on CXCR4 to speak of, a polymorphism on its sole ligand, 
SDF-1 (SDF-1α) can increase the chemokine production and compete against the virus 
for binding. CCR2 also possess a mutation that alters the valine at position 64 to 
isoleucine. This has an impact on disease progression, where heterozygous individuals 
progress to AIDS 2-4 years slower, has little effect on transmission, and is most effective 
in early infection (Smith et al., 1997; Kostrikis et al., 1998; Mulherin et al., 2003).  
 
Although CXCR4 and CCR5 are the dominant chemokine coreceptors used, some HIV-1 
isolates have been found to utilize other chemokine receptors including CCR2b, CCR3, 
CCR8, Bonzo (STL33), BOB (GPR15) and GPR1 (Alkhatib, et al., 1997; Alkhatib, et al., 
1997a; Bjorndal et al., 1997; Farzan et al., 1997; Horuk et al., 1998; Pohlmann, 
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Krumbiegel & Kirchhoff, 1999). All of these alternative coreceptors are rarely utilized, 
and only used in late stage of the infection. It may be that these coreceptors allow certain 
selective advantages, such as infecting other CD4+ cells besides T lymphocytes and 
macrophages, and broaden the range of susceptible cells and site of infection. However, 
there have been little evidence of these advantages from in vivo studies as of yet.  
 
1.3.2 Fusion mechanisms 
Even though the three components that are required for viral entry have been known for 
some time, the precise mechanism that cause fusion between the virus and host cellular 
membrane remains unclear. The initial steps of interactions between gp120, CD4 and 
chemokine receptor are fairly well understood. Study by Kwong et al. (1998) showed that 
22 CD4 and 26 gp120 amino acid residues are required for interactions. Approximately 3 
CD4  molecules needs to bind to a gp120 protein to induces a conformational change, 
where the V1/V2 loop are displaced to fully reveal the chemokine receptor binding site. 
Four to six chemokine receptors are then needed to bind to complete the conformation 
change of gp120. From this point, the specifics are somewhat unclear. The most widely 
accepted model at present is based on the fusion mechanism of the influenza virus. This 
is plausible as the ectodomain of gp41 possess certain structural similarities to the 
fusogenic form of haemagglutinin, the protein responsible for fusion on the influenza 
virus membrane (Turner & Summers, 1999; Kilby & Eron, 2003). Both proteins contain a 
central, three-stranded parallel coiled-coil, and each monomer is made up of two helices 
in anti-parallel arrangements.  
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When both CD4 and chemokine receptors have bound to gp120, and conformation 
change has occurred, it provides energy to gp41. The hydrophobic fusion peptides at the 
amino terminus of gp41 use the energy to insert itself into the host cell membrane, 
making the glycoprotein integral to both the viral and cellular membrane. The trimeric 
coiled-coil then bends back on itself, forming a six-helix bundle where the gp41 fusion 
peptide and the transmembrane domain are at the same end. The folding of the coiled coil 
thus brings the two membranes into proximity where the viral bilipid membrane mixes 
with those of the host membrane, and allows the content of the virion entry (figure 1.4) 
(Jardetzsky & Lamb, 2004). Other viruses, including orthomyxovirus, filovirus, and 
paramyxovirus, also utilize similar fusion protein to gain entry. However, the fusion 
mechanisms mechanism used by the other viruses are pH-dependant, using acid from 
endosomes to affect and enhance the process of lipid mixing between the two membranes, 
whereas the HIV-1 fusion process is pH-independent. Furthermore, there are other 
structural differences that seem to inhibit the necessary orientations of the gp41 
ectodomain for fusion following the haemagglutinin model. An alternative model has 
thus been suggested, where upon the successful binding of CD4 and the chemokine 
coreceptor, the virus shed the gp120 proteins. This allows gp41 to orientate itself parallel 
to both membranes, and allows the insertion of the ‘fusogenic peptides’ into the cellular 
membrane (Caffrey et al., 1998; Turner & Summers, 1999).  
 
1.3.3 Post entry cell-HIV interactions  
Once the virus fuse with the cells through the use of CD4 and chemokine coreceptors, it 
introduces a reverse transcription complex into the cytosol of the cell. The viral reverse 
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transcriptase (RT) then produce viral DNA in association with the complex. The viral 
genome, as well as the viral proteins integrase (IN), reverse transcriptase, matrix (MA) 
protein, and Vpr protein are incorporated in a preintegration complex (PIC) and imported 
into the nucleus. Within the nucleus, the viral DNA is covalently integrated into the host 
genome by the viral integrase. This can be considered the early phase of the HIV life 
cycle, as the process may pause here indefinitely depending on the status of the infected 
cell (Zack et al., 1990; Saksena & Potter, 2003).  
 
 
 
Figure 1.3: Potential mechanisms for CD4 and chemokine receptor-induced fusion 
of the viral and cellular membranes. (a) Spring-loaded mechanism similar to that 
proposed for hemagglutinin, where conformational changes in the TM ectodomain 
lead to a major displacement of the N-terminal fusogenic peptide toward the cellular 
membrane. (b) Shedding mechanism, where CD4 and chemokine binding result in 
 21
the loss of SU proteins, enabling reorientation of the TM and membrane fusion 
(from Turner & Summer, 1999). 
 
Replication of the virus begins with the production of unspliced and spliced viral mRNA 
in the nucleus, and are then exported for translation. Spliced genes coding for tat, nef, and 
rev are produced first, as they provide regulation for subsequent steps of translation. Rev, 
in particular, is important for translation, as it directs splicing, and allows the production 
of unspliced (gag and gag-pol proteins), as well as singly spliced (Env, Vpu, Vif and Vpr) 
proteins (Morrow et al., 1994).  
 
Gp160, the envelope precursor, is synthesized in the endoplasmic reticulum (ER). The 
protein is cleaved into the transmembrane (gp41) and surface (gp120) proteins, which 
remains covalently associated. To prevent premature binding of env to CD4, which is 
also produced in the ER, Vpu is involved to facilitate CD4 degradation. Functional CD4 
on the cell surface is also removed by endosomal degradation, initiated by the Nef protein.  
 
Formation of immature virions relies on 1000-1200 copies of gag being assembled on the 
cell surface. This process is aided by the gag-pol polyprotein. The gag collective then 
encapsulate two copies of the unspliced viral genome. After budding, the gag-pol 
polyprotein is cleaved to produce enzymes as well as the matrix, capsid (CA) and 
nucleocapsid (NC) proteins. These structural proteins arrange themselves in the 
maturation process to give rise to a functional, infectious virion. The production of 
mRNA, translation, actions of inhibitory proteins, and eventual production of mature, 
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infectious virions can be considered to be the late phase of the virus life cycle (Morrow, 
Park & Wakefield, 1994; Turner & Summer, 1999). This section is presented graphically 
in figure 1.4. 
 
 
Figure 1.4: a schematic of the basic steps in HIV life cycle (From Turner & Summer, 
1999).  
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1.4 Interactions with host cells 
 
On the molecular level, HIV poses a number of interesting questions in its interaction 
with various cell populations of the immune system. These unresolved issues has led to 
the problematic definition of the mechanisms by which the virus cause AIDS, and while 
hypotheses has been proposed to address them, none have yet to be shown to be fully 
accurate under close scrutiny, or backed up by sufficient experimental/clinical data. 
 
1.4.1 Macrophages and T cells: primary targets of HIV-1 
The first and perhaps the most important question is what is the extent of interaction 
between the virus and the CD4+ cell populations. It has become a given that HIV infect 
CD4+ cells – both the macrophage and T cell populations – but the consequences of the 
infection vary quite drastically in these two populations. 
 
Macrophages are any mononuclear phagocytes that are present in tissues, which process 
and present antigens to T cell receptors. They arise from hematopoietic stem cells in bone 
marrow, and pass through a number of immature stages (monoblast, promonocyte, 
monocytes) before entering the blood stream. The monocytes circulate for about forty 
hours when they then enter the nearest tissue, and fully mature into macrophages. Due to 
this very general classification, there are a large number of cells that can be classified as 
macrophage, while possessing more specific names on accounts of their function, 
location in the body, or morphology. These include histiocytes, kuppfer cells, osteoclasts, 
peritoneal and alveolar macrophages (NDI foundation, 2003; MeSH database, 2004). But 
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in such a broad spectrum population, only a small percentage of macrophage is infected 
(Chun et al., 1997). At any one point during the infection, macrophages represent no 
more than 10% of productively infected cells.  
 
 In theory, infected macrophages is able to produce virus throughout their existence 
(Blankson, Persaud & Siliciano, 2002). They also do not appear to vary greatly from 
uninfected cells, as their half-life remains consistent to normal macrophages, and suffer 
less cytopathic effects in vitro (Ho, Rota & Hirsch, 1986). However, the presence of the 
virus appears to influence macrophage activity, causing decreased efficiency of 
phagocytosis, and perhaps the initiation of consequent immune responses (Crowe, 1995). 
 
Even though (infected) macrophages seems to suffers little in the presence of the virus, 
the interaction of infected macrophages with other cells of the immune response do have 
undesirable consequences, particularly in light of the fact that as an APC, it is involved in 
nonspecific immune responses and would present the virus to vulnerable CD4+ T cells. 
Furthermore, it can produce chemokines like MIP to attract more monocytes, 
macrophages and T cells, to enhance the response to the pathogen. In HIV infection, this 
merely provides more viable targets for the virus to attack. Furthermore, infected 
monocytes-derived macrophages (MDMs) have been shown to be the culprit in 
introducing the virus to the cells of the central nervous system (CNS). In particular, the 
virus is able to invade the microglial cells that express all the necessary receptors (CD4, 
CCR5/CXCR4), albeit at lower level than the peripheral cell populations. The invasion of 
CNS is the cause of HIV-related encephalopathy in children, and AIDS dementia 
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complex (ADC) or HIV-associated dementia (HAD) in adults (Crowe, 1995; Martin-
Garcia et al., 2002). These disorders can proceed from mild symptoms like peripheral 
neuropathies, to full-blown dementia in advance stages of HIV infection/AIDS if 
unchecked by antiviral drugs.  
 
The infected cells in CNS are usually considered to be replication competent reservoirs. 
Neuropathogenesis from HIV infection also appears to be the doings of the brain 
macrophages rather than the other CNS cell populations. Activated brain macrophages 
releases a number of cytokines and chemokines that are considered neurotoxic, including 
tumour necrosis factor (TNF) –α and  -β1, interleukin (IL)-1 α and β, arachdonic acid 
metabolites, and N-methy-D-aspartate (NMDA) agonists like glutamate, cysteine and 
quinolinate. Viral proteins released from infected macrophages also have a similar effect. 
The neurotoxins stimulate astrocytes, causing release of glutamate, leading to neural 
injuries, and the injuries cause the neurons themselves to release more glutamate, thus 
propagating the cycle (Crowe, 1995; Martin-Garcia et al., 2002).  
 
CD4+ T cells are the other dominant cell population that is targeted by HIV, and is much 
harder hit as the disease progresses. While macrophages are little affected by the virus, 
CD4+ T cells number plummets dramatically, and is associated with clinical 
immunodeficiency at the end of viral infection. T lymphocytes are involved in cell-
mediated immunity, and are divided into subsets according to their functions: 
helper/inducer, effector/suppressor, and cytotoxic cells. The CD4+ T cells are of the first 
group, involved in major histocompatibility class (MHC) II restricted interactions, as well 
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as the induction of a number of major immunological responses (see figure. 1.4). Defects 
or depletion of T cells would have severe repercussion on the factors they secrete. The 
helper/inducer T cells are also divided into two subsets.  T helper 1 cells secrete 
interleukin-2 (IL-2), gamma-interferon (IFN-γ), and interleukin-12 (IL-12). They are able 
to eliminate antigen-presenting cells, possess lymphokine-mediated effector activity and 
support cellular immune responses. Th2 cells secrete interleukins-4, -5, -6, and -10 (IL-4, 
IL-5, IL-6, IL-10). This allows the cells to influence B-cell development, antibody 
production and able to enhance humoral responses (Douglas et al., 2003; Fauci, 1988; 
Sarih, Maataoui & Benlimane, 1996; MeSH database). 
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Figure 1.5: CD4+ T cells’ role in the immune system. It is critical involved in 
induction of a number of immune responses, as well as certain non-lymphoid cell 
function. These functions are mainly achieved by T cell secretion of soluble factors. 
(Adapted from Fauci, 1988).  
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It has been suggested that Th1 cells are more adversely affected than Th2 cells in HIV 
infection, a situation detectable even before the CD4 counts begin to decline (Clerici et 
al., 1989; Imami et al., 2002).  The depletion of Th1 cells may explain the inability of the 
immune system to deal with the virus. Cell mediated response is the primary pathway to 
deal against viral infection. Without Th1 cells, elimination of virus would obviously 
become more difficult. However, there are contrasting data to this observation, which 
showed no significant change in cytokine expression to favour those secreted by Th2 
cells (Sarih, Maataoui & Benslimane, 1996; Douglas et al., 2003). The shift in cytokine 
profile during HIV infection thus remains a point of contention. There are also 
indications that the balanced survival of both Th1 and Th2 is necessary for long-term 
non-progressors (LTNP). This is not surprising as the existence between the two helper T 
cell populations is the norm in healthy individuals, and would allow the immune system 
better management of the virus. 
 
Aside from the quantitative perturbation of T cell depletion, there also exist functional 
abnormalities. T cells that interact with soluble antigens are deficient from early stages of 
HIV infection. Those that remain are also less responsive to exposure to antigens and 
mitogens. The suppression of CD4 expression on infected cell contributes to the 
functional anomalies as well (Fauci, 1988). Interaction of CD4 with MHC II molecules is 
one of the defining features and function of T cells; a decline in CD4 receptors will 
therefore decrease the efficacy of these cells. 
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CD4+ T cells can also be differentiated according to their active status. This in turn 
affects the cells’ vulnerability of HIV-1. The population is usually dominated by naïve 
resting T cells, which express CD45RO and CCR5. These cells then circulate until they 
encounter antigen. They then become activated T cells, expressing CD45RA and CXCR4 
(Berkowitz et al., 1999; Blaak et al., 1999). The cells also undergo blast transformation 
and proliferation to respond to the pathogen. A percentage of the surviving T cells then 
reverts to a resting state, but as a memory T cell, expressing CXCR4. A small subset of 
memory T cells express CCR5 also exists. The resting memory T cell is dormant until it 
encounters the same antigen in the future, and allows a much quicker immune response to 
the pathogen.  
 
1.4.2 Mechanisms of CD4+ T cell depletion 
The definitive clinical classification of disease progression into AIDS is the profile of 
CD4+ cell count in the blood as time goes by. When the infected individual has less than 
200 CD4+ cells per microlitre of blood, the infection is considered to have entered AIDS 
(a normal individual typically has a CD4 count of 1000 and upwards). But despite the 
fact that decline, and eventual depletion of CD4+ T cells is a clear manifestation of the 
severity of the infection, the precise mechanism/s by which the virus achieve this remains 
unknown. The present group of theories in existence to answer this question can be 
roughly divided into two camps, those of direct elimination mechanisms versus the 
indirect mechanisms.  
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In the first scenario, it is suggested that CD4+ T cells in the blood are eliminated as a 
direct consequence of the cells being infected by the virus, and those uninfected remains 
out of harm’s way. The infected cells may perish through a number of mechanisms: 1). 
cell lysis as new virions bud off, thus stripping the host of its cellular membrane (Zagury 
et al., 1986). 2). cytotoxicity brought about by the accumulation of unintegrated viral 
DNA (Pantaleo et al., 1993). 3). elimination through autoimmune clearance or cytotoxic 
antibodies (Fauci, 1988). 4). It may also be possible that the replicating cells are induced 
into G2 arrest and eventually undergo apoptosis induced by the viral protein Vpr 
(Ameisen, 1992), or apoptosis signals via the receptors (e.g. CD4 and TCR) of the 
infected cells (Groux et al., 1992). 
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Figure 1.6: The possible mechanisms by which CD4+ T cells may be depleted in an 
HIV-infected system. 
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However, these direct kill-mechanisms does not stand very well to the experimental data, 
which shows a very low level of viral expression in CD4+ T cells in both lymph nodes 
and peripheral blood in vivo (less than 0.01% of mononuclear cells) (Harper et al., 1986; 
Embretson et al., 1993). This is possibly due to the fact that while HIV can enter the 
resting lymphocytes, reverse transcription does not proceed fully, leading to an abortive 
infection, which may be considered as latent infection of these cells (Adams et al., 1994). 
Considering greater than 98% of the lymphocytes in vivo at any one time are resting, it is 
logical that only a small fraction of the cells are capable of actively producing the virus. 
Furthermore, HIV principally infect activated T cells, yet the depletion of cells starts with 
naïve CD4+ and CD8+ T cells (Chen & Cloyd, 1999). Consequently, direct killing 
mechanisms cannot account for the drastic decrease in the CD4+ T cell population.  
 
The indirect theories suggest that the virus eliminate surrounding uninfected T cells. This 
could occur via 1). synctia formation between the infected and uninfected cells (Lifson et 
al., 1986). 2).  autoimmune killing of uninfected cells (Golding et al., 1988). 3). selective 
elimination mediated by an HIV-encoded superantigen (Finkel et al., 1995) – although 
it’s more likely that the viral superantigen increase infection of cells, or 4). induction of 
apoptosis in uninfected cells by HIV proteins (e.g. Tat).  
 
While indirect killing mechanisms seems quite plausible in terms of mathematics, as 
most CD4+ T cells remain uninfected, there has been little support for any of these 
hypotheses, both in vivo and in vitro. Synctia formation rarely occurs in patients, and then 
only appears in the latter part of the infection (Somasundaran et al., 1987); autoimmune 
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response against uninfected T cells is an infrequent event (Cham et al., 1991), and no 
convincing data is present to verify the existence of a HIV superantigen (Boldt-Houle et 
al., 1993). Although high level of tat and gp120 proteins can induce apoptosis, no strain 
of HIV produces such high levels in vivo during productive infection (Li et al., 1995; 
Wang et al., 1994).  
 
In light of these unsatisfactory models, new theories have been proposed to resolve the 
impasse. Wang and colleagues (1997) showed that HIV-1 binding or entering resting 
peripheral lymphocytes activates the expression of L-selectin (CD62L). This is the 
receptor by lymphocytes for homing to lymph nodes; it has also been demonstrated to 
enhance the lymphocytes’ homing effect in SCID mice. It is possible that due to abortive 
infection of resting lymphocytes, CD4+ T cells becomes strongly attracted to return to 
peripheral lymph nodes, thus decreasing the number of circulating CD4+ T cells. Cloyd et 
al. (2001) went one step further to suggest that the abortive infection of resting T cells not 
only enhance CD62L expression, but also upregulate the pre-apoptotic Fas molecule.  
 
When these T cells enter the lymph nodes, a second signal received through the homing 
receptor causes them to go into apoptosis (Chen & Cloyd, 1999). A similar scenario is 
when antigens activate the immune response within lymphoid tissues. CD4+ T cells 
become sequestered within these tissues while the activated CD8+ T cells are allowed 
into circulation. Although the CD4+ T cells do not actually die in this scenario, there is 
impression of depletion, as number in the blood decrease.  This switch of dominant T cell 
population would therefore lead to the façade of a massive CD4+ T cell depletion and the 
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related symptom shown as an inversion of CD4/CD8 ratio seen in the late stage of HIV 
infection (McCune, 2001).  
 
Another theory is that the depletion CD4+ memory T cells is driven by infection-induced 
immune activation. Studies of different infected groups have shown that the turnover rate 
of CD4+ T cells is independent of the viraemia level. This suggest CD4+ T cell depletion 
in the chronic phase of the infection is related to the overall activation and turnover of T 
cells, not the rate of viral replication (Grossman et al., 2002). As mentioned in the 
previous section (1.4.1), naïve CD4+ T cells (and memory T cells that recognize the 
antigen) are activated by antigens. After proliferation and eliminating the antigen, the 
process also removes a high percentage of the activated T cells. Replenishment of resting 
memory T cells relies on the conversion of activated cells that has survived. 
 
It is likely that HIV eliminates a significant percentage of the activated T cells, beyond 
the usual percentage that survives an immune response. This allows only a very small 
number to be converted into resting memory cells. Furthermore, production of naïve T 
cells from the thymus have been found to be reduced in HIV patients, with an even more 
prominent deterioration of the thymus when the X4-using virus is in play (Berkowitz et 
al., 1998; Berkowitz et al., 1998a). In association with the chronic immune activation in 
these individuals, the process of replenishing resting T cells are impaired due to a 
decrease of replacements. This would progressively lead to a smaller and smaller 
memory T-cell population for future activation, which will eventually disappear. 
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Even with these alternative pathways for removing the CD4+ T cells from the peripheral 
blood, it seems unlikely that any single mechanism is fully responsible for the depletion. 
All these theories deal with the elimination of T cells in the blood, but do not really 
address the source of the T cells, the thymus. There are indications that the thymus is 
negatively affected in HIV infection. This becomes more prominent if it involves a X4-
using virus, as mentioned above. The deficiency in T cell production, in combination 
with any of the mechanisms mentioned above would be a more plausible scenario for the 
disappearance of T cell. CD4+ T cell depletion is therefore likely to be a multi-facted 
process, that limits production of new T cells, and at the same time, eliminate circulating 
T cells.  
 
Perhaps the biggest discrepancy in the description of CD4+ T cell depletion lies with the 
subtypes that possess no ability to enter the majority of these cells. It has been mentioned 
previously (section 1.1) that HIV-1 can change chemokine coreceptor usage. HIV-1 
subtype is the most proficient strain to undergo this change, where around 50% do 
eventually become X4-using and SI phenotype. Less prevalent strains like A and E, also 
has a tendency to change, albeit at a lower prevalence than subtype B. This allows the 
virus entry into the majority of CD4+ T cells and supplies accountability of the virus for 
CD4+ T cell depletion.  
 
This does not explain the depletion that occurs in Subtype C infections. Switch in 
chemokine coreceptor usage is a rarity, usually around 6-7% of the case (Abebe et al., 
1999; Peeters et al., 1999). But it may be as high as 14-16%, depending on the 
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geographical region and sample size of the study (Tien et al., 1999; Cillier et al., 2003). If 
HIV relies on using CXCR4 for infecting the majority of T cells, then there is an 
inconsistency in subtype C pathogenesis. This leads to the question of how the virus is 
eliminating the CD4+ T cells, and whether direct infection of CD4+ T cells are necessary 
in this event. While this is particularly important for understanding subtype C infections, 
it would also be helpful to explain infection involving other subtypes that also do not 
under this change. 
 
1.4.3 Other cells susceptible to HIV infection 
There are also other cells that are affected by the virus, although they do not feature as 
significantly in the HIV pathogenesis as macrophages and CD4+ T cells. CD8+ T cells, 
which constitute the remainder of the T cells, are also affected to an extent, but not to the 
disastrous proportion that its CD4+ counterpart suffers. Although chronic immune 
activation is a hallmark event in HIV infection, leading to the whole T cell population 
having a shorter half-life (Hellerstein et al., 1999), CD8+ T cells does not appear to suffer 
depletion. However, CD8+ T cells does become activated for longer periods of time, and 
also possess shorter telomeres. This may allow these cells more time to fulfil their 
immunological functions, as well as increase proliferation to keep up with the shorter 
half-life.  
 
The population has also been found to coexpress CD4, and the level of expression can 
match those of mature CD4+ T cells (Imlach et al., 2001). But they do not suffer the 
cytopathic effects from the virus (Mercure et al., 1993), which would allow better 
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maintenance of the population over time. While they are unlikely to be the primary target 
of the virus – they represent less than 0.01% of PBMCs, and their infection relies on a 
primary infection of CD4+ T cells – infected CD8+ T cells is able to transmit the virus to 
CD4+ T cells. Thus, the possibility of infected CD8+ T cells is a cause for concern, as it 
means the population would need to be taken into consideration for treating the disease 
 
The dendritic cells (DCs) of the mucosal are another cell population affected by HIV-1. 
These cells are present on the squamous epithelial (including the epithelial and genital 
mucosae), and are primarily represented by the immature dendritic cells (iDCs), or 
Langerhans cells (LCs). They are considered to be specialized antigen capture/processing 
cells, and are speculated to be the first targets of HIV in sexual transmission (Lin et al., 
2000). This is quite plausible in light of the macaque SIV model, where the first targets 
after vaginal challenge are the mucosal dendritic cells, and iDCs accounts for up to 90% 
of infected cells after 18 hours in the macaque (Lin et al., 2000; Izmailova et al., 2003). 
The iDCs’ function is to acquire foreign proteins by phagocytosis or pinocytosis and 
reduce them into antigen for presentation on the cell surface. As they express CCR5, 
iDCs are drawn to sites of inflammation where chemokines like MIP-1α, -1β and 
RANTES are being produced. Once they picked up sufficient number of antigens (Ags), 
they migrate to secondary lymphoid tissues using the draining lymphatic system.  
 
The dendritic cells mature by the time they arrive in the lymph node, now expressing co-
stimulatory molecules to attract and trigger the appropriate T cells. CCR5 is 
downregulated at this point, whereas CXCR4 is upregulated. Either way, dendritic cells 
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(DCs) are viable targets throughout infection - they are more resistant to the T-tropic 
viruses, although reasons for this remain unknown (Rowland-Jones, 1999). Dendritic 
cells’ role as antigen carrier has also been found to be further exploited by HIV. The 
process enhances the capture and presentation of the virus to the T cells, and thus further 
facilitates the virus dissemination in an infected system. Furthermore, integrated proviral 
DNA have been found in dendritic cells, suggesting that DCs may be sites of production 
infection in vivo (Zambruno et al., 1995). However, it appears that replication is 
incomplete, and is only productive in mature dendritic cells so as to transmit the virus to 
the T cells (Rowland-Jones, 1999).  
 
The follicular dendritic cells (FDCs) of the lymphoid tissues are also affected by the virus. 
Follicular dendritic cells are present in the B cell area (primary follicles and germinal 
centres) of lymphoid tissues, and are unlike the typical dendritic cells that present 
antigens to T cells. FDCs only hold the antigen in forms of immune complexes on the 
cell surface for long periods of time and present the antigen to B cells in immune 
response (Entrez-Pubmed MeSH, 2003).  
 
The FDC network in the lymphoid germinal centres was earlier mentioned as one of the 
reason why there is a large increase of viraemia in late HIV progression/AIDS. The 
decrease of FDCs is one of the main causes of lymphadenopathy. Although 
lymphadenopathy is a worrying symptom by itself, it is made worse by the fact that the 
FDCs in the germinal centres acts as a filter to retain the virus, either in immune 
complexes, or as virions on surface of follicular dendritic processes. This filter can limit 
 37
the amount of viraemia in circulation, but it also concentrates the virus to a region where 
any susceptible cells migrating through the lymphoid tissues may become infected. In 
addition, HIV is able to use the follicular dendritic cells for replication, thus causing the 
eventual disintegration of the FDC network. The disorganization of the network would 
thus lead to less efficient trapping of the virions, as well as the release of the previously 
trapped viruses (Fox et al., 1991).  
 
Lastly, other mucosal cells, particularly in the GIT, can be infected by HIV-1. The upper 
GIT is an important site of viral entry in vertical transmission in utero (amniotic fluid and 
blood exposure) and post-partem (breastfeeding), as well as in homosexual transmission 
(oral-genital contact). Although it was found that intestinal macrophages do not express 
CCR5 and cannot be infected by R5 viruses in vitro, intestinal epithelial cells (IECs) do 
express CCR5 and CXCR4, and is able to support both R5- and X4-using viruses in vitro. 
But despite this, primary IECs only express CCR5, and not CXCR4. While there are no 
CD4 present on the IECs, as previously mentioned, the virus is able to use an alternative 
receptor, galactosylceramide, in order to gain entry into these cells. These IECs have also 
been shown to selectively transfer the R5 virus for further infections (Meng et al., 2002). 
The observation of an alternative receptor to CD4 raises the question whether HIV-1 can 
continue with infection even without its primary receptor targets in vivo.  
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1.5 HIV latent reservoir 
 
One of the best studied and documented area in HIV pathogenesis is the latent reservoirs 
that are formed in the resting CD4+ T cells. It is this obstacle that stands in the way of the 
full eradication of HIV in this age of HAART. A viral reservoir is a cell type or site 
within the body in which some form of the virus accumulates and persists with greater 
stability than does the main pool of actively replicating virus (Blankson, Persuand & 
Siliciano, 2002). Cells that fall into this category would be those that have been 
mentioned in the previous section – brain macrophage, dendritic cells, lymphatic 
follicular dendritic cells, mucosal cells and so forth – which are replication competent. A 
latent reservoir refers to cells harboring the virus, and while they are not actively 
producing virus, they retain the capacity to do so (Simmons & Siliciano, 2004).  
  
The knowledge of HIV latency was initially confined to what is termed preintegration 
latency, where the virus enter resting CD4+ T cells and produces a small amount of viral 
DNA. But without any activation signals (e.g. contact with an antigen), the proviral DNA 
loses its ability to actively transcribe after a few hours, although the genetic material may 
persist in the cell for up to two weeks (Bukrinsky et al., 1991; Zack et al., 1990). It was 
then found that the latency of the virus also exists in a much long-lived form (post-
integration latency), where reverse transcription has occurred in the activated CD4+ T 
cells and the viral DNA is integrated into the host cellular genome. The activated T cells 
would then return to a resting state carrying the viral genome (Chun et al 1995; Chun et 
al., 1999). But this event has been found to be rare, as the cells must survive both 
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cytopathic effects of the virus and cytolytic host effector mechanisms to be able to revert 
to the resting state. An activated, infected CD4+ T cell dies quickly to viral cytopathic 
effects, or cytolytic T lymphocytes (CTLs), and has a half-life of one day. 
 
Consequently, the frequency of resting T cells carrying replication competent provirus is 
very low: around 5 per 106 cells in the lymph nodes, and 7 per106 in the blood (Chun et 
al., 1997). There is, however, also a third state, where activated CD4+ T cells carry the 
integrated virus. This can be considered the intermediate step between infection and post 
integration latency, and is only detectable in the late infection, while nonexistent in long 
term survivors (Chun et al., 1995). This seems to support the fact that activated T cells 
that become infected have difficulties entering the resting state due to the reasons stated 
above. It is only when the virus has caused sufficient damage to dthe immune system, 
that detectable level of latently infected CD4+ T cells are seen.  
 
The mechanisms and actions of the latent reservoir have also been explored in great detail. 
It was initially thought that the production of virions by the reservoirs was restricted by 
the status of the cell, as the rescue of the replication competent viruses requires stimuli 
that trigger global T cell activation. However, new data revealed that the determinant of 
replication may involve other factors like the nuclear preintegration complex (PIC), 
where the viral genetic material is actively transported into the cell nucleus in the absence 
of cell division (Bukrinsky et al., 1992). This could explain the replication of HIV-1 in 
nondividing cells such as monocytes/MDMs and dendritic cells. The slow kinetics of the 
resting T cells would also impede the replication, as the import of nucleotides and other 
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necessary component needed for reverse transcription would be severely hampered by the 
low energy level of the cell (Pierson et al., 2002). Events like viral mRNA splicing and 
subsequent nuclear export may also influence the efficiency of the latent reservoir in 
producing new virions. So, while reliance of HIV replication on proliferation of T cells 
cannot be totally dismissed, it seems likely that the limiting factors and controlling 
components to the latent reservoirs is multi-faceted.  
 
An impressive amount of effort has thus been directed to determine the point at which 
these latent reservoirs are established, and what interactions exist between the reservoirs 
and HAART. Even when HAART was implemented ten days after the initial infection, 
post integration latent reservoirs were still established. Furthermore, once these latent 
reservoirs form, present therapy can do very little to eliminate them. This is due to the 
fact that antiretrovirals target active replication, and there are no such activities occurring 
in latent reservoirs. Or at least, the extremely low levels of replication occurring in these 
cells (also know as ‘cryptic’ replication), is sufficiently minimal to escape the effects of 
the drug. 
 
The cells acting as latent reservoir also behave extremely different to the active infected 
T cells. A typically virus-producing cell and plasma virus has a half-life of 1-2 days (Ho 
et al., 1995; Wei et al., 1995). This can be even shorter under antiretroviral treatment, 
where free virus lives for less than 6 hours, while infected cells survive for about a day. 
None of these data apply to latent reservoirs, though. The infected resting T cells have 
been found to be incredibly stable, with a mean half-life of 43.9 months. With this in min, 
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it was predicted that 73 years of continuous HAART would be required to fully eradicate 
the virus. Even the most optimistic lower limit predicts around 21.5 years (Finzi et al., 
1999). Although another group has estimated the latently infected T cell half-life to a 
much shorter 6.2 months, it would still require 6-10 years of therapy (Zhang et al., 1999).  
 
 
 
Figure 1.7: The variations of latent reservoir that can be established by HIV-1 in 
CD4+ T cells (From Blankson, Persaud & Siliciano, 2002). The leftmost side depicts 
the normal functions of the CD4+ T cell, alternating between resting (small), and 
activated (large). R5-viruses can infect activated CD4+ T cells, or some memory T 
cells with sufficient CCR5 density (preintegration latency), and the viral genome 
become integrated in the former. If the activated CD4+ T cells survive to go into a 
resting state, postintegration latency is established.  
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Even if one of these data sets is accurate, one is still presuming the latently infected cells 
will not undergo the occasional cycles of proliferation. A typical memory T cell has a 
intermitotic half-life of about 6 months, but some continue to maintain the memory 
population through homeostatic proliferation. This can be achieved in the absence of 
antigen and probably without activation of the latent HIV genes. Such a process would 
lead to the existence of integrated virus beyond the 6 months of memory T cells lifespan 
(Blankson, Persaud & Siliciano, 2002). It also assumes continuous low level of 
replication that escape HAART would not contribute to infection activated T cells. The 
memory population would thus continue to receive infected cells, which replaces those 
that had died out.  There is also the assumption that the reservoir remains small 
throughout the disease, as calculations were based on only 105-106 cells acting as latent 
reservoirs. The most recent long-term study by Siliciano and colleagues (2003), showed 
that even after 7 years of ‘successful’ treatment, there seems to be minimal decay of the 
latent reservoir. This is likly be the norm, rather than the exception. Aside from the 
seemingly impossible task of eradicating the latent reservoir, what is just as disconcerting 
is that these reservoirs may carry ‘archival’ strains from a time before treatment, and is 
thus able to defy treatment (Pomerantz, 2001). Therefore, it is of utmost importance that 
study into the latent reservoir continues, so as to determine ways to better contain, to 
eliminate these cells.  
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1.6 Fluorescent in situ hybridization 
 
Fluorescent in situ hybridization, or FISH, was originally developed by Pardue and Gall, 
and John et al., independently of one another in 1969. It has become an established and 
useful molecular technique, and a number of variations have been introduced, particularly 
in conjunction with other molecular techniques, like PCR and flow cytometry. The basic 
principle of an in situ hybridization is to design and produce labeled – radioactive or non-
isotropic labeled – nucleic acid probes. The resulting probes are placed onto the tissues or 
cells in question, and allowed to hybridize. The sample is then washed to rid of the excess, 
unbound probes, and then examined under a light or fluorescent microscope for 
radioactive or fluorescent probes, respectively.  
 
The manufacture of probes and its nucleic acid depends on its target and the techniques 
available. For DNA probes, it can be produced as synthesized DNA oligonucleotides; 
nick translation to produce DNA fragments; random primers to generate random sized 
fragments; or PCR to make longer fragment. The production of RNA probes is a bit more 
standard: the sequence of interest is subcloned to have RNA polymerase promoter flank 
the fragment (T7, SP6, or T3). The resulting plasmid is then digested to produce varying 
length of RNA probes, where 200-600bp is the optimal length. There is now an 
alternative to subcloning to produce RNA-specific probes – PCR derived RNA-specific 
DNA probes. This is effectively the same principle used to produce the DNA specific 
probes, merely adding in the extra step of reverse-transcription PCR (RT-PCR) so as to 
produce the DNA template required (Cone & Schlaepfer, 1997; Knuchel et al., 2000). 
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 The most obvious advantage to FISH is that it is an inherently specific technique, as the 
probes designed should only target the sequence of interest, much like PCR primers. 
Secondly it allows the visualization of the target in the context of its typical environment. 
However, it is a technically demanding process, and a number of things need to be taken 
into consideration before a good result can be achieved. Firstly, the preparation of certain 
probes types/species is cumbersome and/or time-intensive: radioactive probes are more 
sensitive, but as the probes are radioactive, it is more cumbersome to work as extra 
protections are required. Subcloning generation of the target RNA and subsequent 
degradation is also cumbersome. Secondly, there is a general problem of low sensitivity: 
in situ hybridization typically has difficulties detecting a target that has less than twenty 
copies in the cells/tissues (Knuchel et al., 2000; Patterson et al., 1993). The techniques 
can suffer from poor resolution, particularly if the quality of the biological sample. 
Methods of tissue preservation – like paraffin embedded slides – and subsequent 
treatment of the sample also needs to be carefully controlled to ensure good hybridization 
occurs.  
 
This is particularly important when dealing with RNA-FISH. Due to the relative 
instability of RNA, the sample need to be as fresh as possible and process within 2-4 
hours in order to preserve the integrity of the RNA. The slides then have to be stored at -
70°C until needed. The technique is also time consuming and labour intensive. The 
probes needs to be first produced in one of the manner described above, then the slides 
needs to be screened to ensure that there are sufficient cells for hybridization. Optional 
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step may be required (e.g. then treated with DNase to remove potential background 
targets) to optimize the hybridization. Once the hybridization is complete, the slides need 
to be put away in the incubation overnight (10 hours or more) to allow maximum 
hybridization between the target and the probes.  
 
FISH has principally been used to detect chromosomal aberrations, like rearrangement of 
genes (e.g. BCR-ABL), or extra chromosome (e.g. trisomy 21). In HIV research, FISH is 
rarely used by itself, and has been utilized in conjunction with PCR, and flow cytometry. 
These variations are principally used to overcome some of the flaws of FISH: PCR-
driven FISH can amplify low copy numbers of the target sequence sufficiently to be 
detectable (Patterson et al., 1993), while flow cytometry can speed the counting of 
positively labeled cells to matter of seconds (Borzi et al., 1997). Although these 
combinations of techniques are useful, they are not necessary in this study. The issue of 
low copy number is somewhat irrelevant in the detection of actively replicating reservoirs, 
as any active site of replication should have an abundance of viral mRNA present in the 
cell. And while flow cytometry is a nice application by enhancing the counting process, 
manual counting is still viable here, even though it is more time intensive. 
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1.7 Prediction of HIV-1 chemokine coreceptor usage  
 
The initial approaches to monitor the change from NSI to SI were to inoculate PBMC 
with the virus or cocultivation of PBMC with infected cells, and to evaluate the amount 
of synctia formation in the cultures. Alternatively, it can be determined by culturing the 
virus with the MT-2 cell lines (a transformed T cell line), as these cells only support the 
replication of the SI virus (Dong et al., 2005). Other indicator cell lines that express 
certain chemokine coreceptor only were also used. Their infection indicates the use of the 
receptors. However, these culturing assays merely provide a positive or negative result 
with respect to the phenotypic characteristics, and do not reflect the genetic changes 
which may significantly enhance understanding of the viral pathogenesis.  
 
More recently, the gp120 of the HIV envelope protein – and specifically the V3 loop - 
has been found to be the key determinant in the virus’ ability to induce syncytium. 
Position 306 and 320 in gp160 (reference virus HXB), which fall into the V3 loop (and 
equates to position 11 and 25 in the V3 loop), seems to possess an absolute correlation in 
the naturally occurring virus’ capability of inducing syncytium. The NSI variants are 
either negatively charged or without charges, while the SI virus has positively charged 
amino acids at either one or both of these positions (Fouchier et al, 1992; De Jong et al., 
1992). At least one of the two amino acid positions is therefore always associated with 
X4-tropic, dualtropic (R5X4), or the SI phenotype. This phenotype-genotype correlation 
is also independent of any changes in the other parts of gp120. Mutation has been found 
to occur in the V2 and C4 region, and may have association to the selection of chemokine 
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coreceptors (Hoffman et al., 2002). However, these variances that occur outside the V3 
loop seem to have much less importance in comparison with the two amino acid 
substitution. There were also indications that a purely visual examination of the amino 
acid composition at positions 11 and 25 is actually one of the more dependable methods 
for predicting the SI and X4-using phenotype, based only on motifs (Resch et al., 2001). 
This defining characteristic correlates the V3 loop genotype with the phenotype, which 
has also come to be known as the 11/25 rule.  
 
The second method of phenotype prediction is the Position Specific Scoring Matrix 
(PSSM). The PSSM is derived from a profile, which is a collection of aligned sequences 
that contain the domain of interest and list the frequencies of amino acid in each position 
for the resulting protein. The PSSM utilize this information and provides a log-odds score 
for finding a matching amino acid in the sequence provided, against the reference data 
produced by the profile. In the PSSM created by Mark Jensen at the University of 
Washington, the score range indicate the R5 viruses have a low value, dualtropic R5X4 
viruses have intermediate score, and X4 viruses possess the highest numbers (Jensen et 
al., 2003). This method relies on the full sequence of the V3 loop as input in order to 
obtain a score on the PSSM. There is also a second PSSM – the sinsi matrix - that 
calculates the score in terms of NSI/SI phenotype, with a similar pattern (NSI has low 
value score; SI has the high value scores). The dividing range for the sinsi scoring matrix 
is slightly different compared to the x4r5 matrix, as the intermediate scores on the x4r5 
matrix may reflect differently on the sinsi matrix.  
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The third and final method used for phenotype prediction was the basic calculation of the 
total charge of the V3 loop. It takes into account all of the amino acids and their charges. 
Only 5 out of the 20 amino acids possess charges at the physiological pH: arginine (R) 
and Lysine (K) carries a +1 charge; aspartic acid (D) and glutamic acid (E) carries a -1 
charge. Histidine carries a +0.5 charge, although a number of prediction software 
considers it as having a +1 charge. A low overall charge of the V3 loop (typically 5 or 
less) is an indicator of NSI/R5 phenotype, while any V3 amino acid chain with +6 or 
higher charges are usually the SI/X4 phenotype (Cilliers et al., 2003). 
 
One other region that was highly conserved in the V3 loop is the chain of 4 amino acids 
starting from position 6 (NNTR). This stretch is an N-linked glycosylation site, and its 
presence (and subsequent glycosylation of the structure) has been linked with the use of 
CCR5 by the virus (Zhang et al., 2004). Its absence does not indicate the virus has 
switched to using an alternative chemokine receptor, but if the site is present, it is highly 
indicative of the virus using CCR5.  
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Aims 
 
The pathogenesis of HIV-1 relies on CD4+ T cells for successful replication and 
transmission. CCR5+CD4+ cells  (macrophages, monocytes, activated T cells, and small 
subset of memory T cells) are the virus’ preferred targets, and this may later include 
CXCR4+CD4+ cells (resting/memory T cells). CD4+ T cells have been acknowledged to 
account for the majority of infected cells, with activated T cells being the virus’ 
preferential target. This population, however, typically represent a minority of T cells. In 
the subtype C virus, a switch in chemokine coreceptor usage from CCR5 to CXCR4 is 
rare, even late in infection. Nevertheless, these infections are not exempt fromCD4+ T 
cell depletion and high viral load, which are key markers in late stag of the infection, 
progressing towards AIDS.  
 
In order to assert whether T cell depletion is occurring through indirect killing 
mechanisms, we propose to investigate the site of HIV-1 presence in these patients.  
 
To achieve this, there are 3 main objectives: 
 
1. Collection of peripheral blood or bone marrow samples from HIV+ patients.  
 
These individuals have to fulfil the following criteria: being in the late stage of the 
disease (200-300 CD4 cell counts or lower), ART-naïve, and not suffering from 
opportunistic diseases. Antiretroviral drugs greatly reduce HIV presence, thus 
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treatment naivety is a necessity. Acute opportunistic infections (OIs) will cause 
proliferation of white blood cells, leading to a distortion of the true number of cells 
carrying the virus. Absence of OIs is therefore required.  
 
2. The design of a FISH probe that is specific to HIV-1 subtype C genome, and 
optimize it on HIV-infected cultures.  
 
The hybridization will then be applied to slides of HIV+ whole blood and bone 
marrow, as well as separated CD4+ cell from these bodily fluids. The result will be 
able to tell us in which cells the viral genomic materials can be found.  
 
3. Prediction of Chemokine coreceptor usage of virus extracted from the patients by 
V3 loop sequencing. The sequencing will also determine the subtype of the 
viruses and any genotypic changes of the region. 
 
The correlation between the FISH and sequencing data will provide a picture of where 
the virus is situated in the knowledge of viral chemokine coreceptor usage.  
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Figure 2.1: The outline of the experimental procedures for this study 
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Figure 2.2: The organization of the HIV genes, with the PCR primers used in this study. The gag and env gene are magnified 
to show the relative positions of the primers used for producing the gag-specific probes and V3 loop sequence.  
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Chapter 2: Materials & methods 
 
2.1 Sample collection, extractions, and lymphocyte isolation 
 
2.1.1 Sample collection 
Fresh blood was collected from patients at the Johannesburg General Hospital HIV clinic. 
Patients without any opportunistic infections, and low CD4 cell count (≤200) were asked 
to donate 3-4ml of blood. Once consent was obtained from an individual, blood was 
drawn into 5 ml EDTA tubes. The blood was processed within 2-4 hours after collection, 
to ensure the integrity of the RNA. Whenever possible, bone marrow extracts were 
collected in the EDTA tubes, following lumbar puncture, and treated in the same manner. 
34 samples was collected, 28 of blood, 6 of bone marrow extract. Ethical clearance was 
obtained for this collection process (See appendix IV).  
 
2.1.2 Cell Lines 
These were obtained from the National Institute of Communicable Disease (HIV unit, 
courtesy of Mr. Jabulani Nhlapo & Mr. Tonie Cilliers). Cell lines with the appropriate 
chemokine coreceptor expression (CCR5 or CXCR4) were infected with virus isolate 
with known phenotype and chemokine coreceptor usage. KC42, and U87.CD4 cell lines 
with CCR5 expression was used for culturing of NSI viruses, while GHOST.3 cell line 
with endogenous CXCR4 expression was used for culturing SI viruses.  
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 The cultures were processed after 4-5 days of growth, and were used for RNA extraction, 
or making slides. 
 
2.1.3 RNA extraction 
Total RNA was extracted from the blood of all (34) the HIV-positive patients collected 
and/or cell line cultures (KC42 infected with R5-virus, or U87 infected with dualtropic 
virus). The extraction was done using the Gentra® Purescript RNA isolation kit and 
follows the provided protocol (Gentra System, Minneapolis, USA). RNA was stored at -
70 ºC until needed. 
 
2.1.4 DNA extraction 
Genomic DNA was extracted from blood of the patients and cell line cultures using the 
Gentra® Puregene DNA isolation kit (Gentra System, Minneapolis, USA). Extractions 
were carried out as protocol provided in the kit. DNA was stored at -20 ºC until needed.  
 
The mixed DNA/protein pellet, remnant from the RNA extraction, can also be used to 
extract the DNA. Cell lysis solution can be added to the protein-DNA pellet, and the 
extraction continues from that point on. The process was also described in the provided 
protocol.  
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2.1.5 Ficoll-hypaque separation 
Ficoll-hypaque extraction allowed the separation of white blood cells from the fresh 
blood. Blood was diluted using Hank’s balanced salt solution at a 1:1 ratio and pipetted 
up and down to ensure a good mix.  
 
A specially designed 10 ml tube was used, where the 3 ml of the bottom was divided into 
a compartment to house the ficoll solution.  
 
3 ml of ficoll was added to the tube, and it was made sure there was no air bubbles 
trapped in the compartment. The diluted blood was then placed it on top of the ficoll. The 
blood was spun at 400 g (1410 rpm) for 40 minutes at 18-20 ºC. The white blood cells 
were visible as a thin layer between the plasma and the ficoll. The white blood cells were 
removed by pipetting and placed in a clean tube with as little of the two layers as possible, 
as the plasma could cause platelets and plasma protein contamination, while ficoll had 
granulocytes. At least 3 volumes of the Hank’s balanced salt solution were added to the 
lymphocytes and the cells were resuspended by pipetting. The sample was centrifuged at 
60-100x g for 10 minutes at 18-20 ºC, and supernatant was then removed. 6-8 ml of 
Hank’s balanced salt solution was added and centrifuged once more at 60-100x g for 10 
minutes at 18-20 ºC. Supernatant was removed once again and the cells were resuspended 
in 1ml of Hank’s Balanced Salt. 
 
The suspension was used make slides directly after the separation. The remaining 
suspension was then stored at -70 ºC.  
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2.1.6 Dynabead cell separation 
The Dynal (Invitrogen) Dynabeads were superparamagnetic polystyrene beads 
manufactured to the same size (4.5 μm±0.2 μm) and labeled with specific antibodies to 
isolate certain cell populations in the blood. In this case, Dynabead with CD4 monoclonal 
mouse antibody were used to isolate the CD4+ cell populations from blood of HIV+ 
patients, as the ficoll-hypaque method was to be lacking – there were inefficient recovery 
of the white blood cells. 
 
As per the provided protocol, the Dynabeads were washed, mixed with blood and used to 
separate the CD4+ T cells from the peripheral blood. The separated cells were stored in 
culture medium at 4 ºC until needed.  
  
2.1.6.1 DETACHaBEAD  
There was an alternative to leaving the cells attached to the Dynabeads, which was 
particularly useful, as the beads may interfere with any subsequent processes after cell 
separation. The variation was referred to as DETACHaBEADs. The DETACHaBEAD 
CD4 solution contained a polyclonal anti-Fab antibody specific for the CD4 antibody on 
the Dynabeads. When added, the DETACHaBEAD competed with the antibody-antigen 
binding at the cell surface and released the antibody and beads from the cell. The CD4 
cells were left viable, unstimulated and without surface antibodies (Dynal Biotech, 2004). 
The separation of the cells and removal of Dynabeads were performed in lines with the 
provided protocol.  
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2.2 Fluorescent in situ hybridization (FISH) 
 
FISH involved a number of procedures to complete, including slide preparation, probe 
manufacture, optimization. This was followed by the hybridization process itself, and the 
subsequent analysis under the fluorescent microscope.  
 
2.2.1 Slide preparation 
2.2.1.1 Cultured cell-line slides 
Cells suspended in culture medium were spun down at 15 000x g for 20 seconds. 
Majority of the supernatant was removed, and cells were resuspended through vortexing. 
The cells were dropped from 20-30cm above the slide and air dried. The slides were fixed 
in methanol for 30 minutes at -20 ºC, and dehydrated in an ethanol series (70%, 90%, 
100%) for 5 minutes each at room temperature. The slides were allowed to air dry and 
then stored away at -70 ºC until needed. 
 
2.2.1.2 Slides from blood and separated fractions 
Slides were made from the fresh blood obtained from the patient, as well as from 
separated lymphocytes. In the first instance, blood was placed onto a clean slide and then 
lightly smeared over the whole surface using the edge of a second slide. The slide was 
allowed to air dry, and then fixed in the following solutions: methanol for 10 minutes at 
room temperature, methanol for 30 minutes at -20 ºC, fix (methanol:acetic acid mix, 3:1 
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ratio) for 1 hour at -20 ºC. The slides were then dehydrated and stored in the same 
manner described in 2.2.1.1.  
 
For both ficoll-separated and Dynabead-separated cells, the cell suspension was dropped 
onto a clean slide from some distance above the slide, and then steamed for 60-80 
seconds. Alternatively, the cell suspension smeared over the surface of the slide in the 
manner described for the blood smear slide. They were allowed to air dry, and then 
dehydrated and stored as mentioned in 2.2.1.1.  
 
2.2.1.3 DNase I treatment 
Before the slides can be used for FISH, it was necessary to treat them with DNase I to 
remove as much of the DNA as possible so as to eliminate excess background signals. 10 
μl of DNase I (10ng/ml) was first heat treated at 95 ºC for 10 minutes, and then diluted 
with 990 μl of Sabax water. 10-15 μl of the dilution was placed onto a coverslip and then 
placed onto the slide. The slide was then incubated upside down (area with coverslip on 
the bottom side) for 30 minutes at 37 ºC. The coverslip was then removed by gentle 
tapping, and the slide was washed in 1X PBS to rid the DNase I enzyme.  
 
2.2.2 Probe manufacture 
2.2.2.1 Reverse-transcription Polymerase Chain Reaction (RT-PCR) 
RT-PCR was required to produce the cDNA needed for manufacture of the FISH probe. 
RT-PCR uses total extracted RNA and amplifies the viral mRNA; more specifically, part 
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of the gag gene. The gag gene was chosen based on the reason that it is one of the few 
viral genes that is has a low mutation rate throughout all the subtypes and variants of HIV.  
Two different sets of primers were used to produce two gag-specific probes. These were 
used separately during hybridization. The Qiagen one-step RT-PCR kit (Qiagen, USA) 
was used to obtain the cDNA (see appendix I for primer sequences and RT-PCR 
parameters).  
 
RNA obtained from cell cultures (mainly KC42 infected with R5-using viruses; R5X4 
were also used) were used as template for RT-PCR and subsequent probe production.  
 
2.2.2.2 Polymerase Chain Reaction (PCR) 
PCR was used to in terms of PCR labeling for incorporation of fluorescently labeled 
nucleotides into the gag-specific fragments. It was also used to produce the alternative 
gag fragment used in nick translation.  
  
The probe production was adapted from a nested PCR protocol (courtesy of Mia Coetzer, 
HIV unit, NICD). The PCR target the gag gene of HIV-1, and was able to amplify 
consistently for R5-using virus as well as the X4 strain. The first round PCR produces a 
~1127 bp fragment, and the nested PCR gave rise to a ~466 bp fragment.  
 
The second gag primer sets was also a nested PCR, courtesy of Dr Maria 
Papathanasopoulos (Department of haematology & molecular medicine, Wits medical 
school). The first round amplified a 2.5 kb fragment, and the second round produces a 
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fragment about 1.2 kb in size, spanning the complete gag gene. (See appendix I for 
primer sequences and PCR protocols). 
 
Both sets of primers were first tested using RNA obtained from both R5 and R5X4 cell 
cultures, and then subjected to PCR labeling or nick translation to produce the necessary 
probes. Negative controls with sabax water replacing the RNA/DNA were run 
cocurrently to the samples to detect for contamination.  
 
2.2.2.3 PCR labelling & probe precipitation 
The labeling process was a straight adaptation of the nested round for the first set of gag 
PCR. The only alteration was the volume of FITC-dUTP (optimized to 0.5-0.6 μl per 
PCR reaction) was added, and corresponding volume of water was subtracted from the 
total volume.  
 
The labeled fragment is visualized in the same manner as normal PCR (see appendix I). 
The product would be the same size, although it would now be a visibly green-yellow 
colour. There were typically bands of fluorescence towards of the bottom of the run, 
brought about by the unincorporated fluorescent nucleotides.  
 
The probe was then precipitated to concentrate it and maximize its efficiency. 1/10 
volume of the sodium acetate (pH 3.5) and 2.5x volume of 100% ice cold ethanol was 
added to the product and then allowed to sit at -70 ºC for at least 30 minutes. It was spun 
at 13 000x g (or higher) for 30 minutes at 4ºC. The probes should be visible as a small 
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yellow pellet at the bottom of the tube at this point. As much of the supernatant was 
removed from the tube without disturbing the pellet; 100 μl of 70% ice cold ethanol was 
then added and slowly pipetted up and down to wash the pellet. The probe was spun at 
maximum speed for 10 minutes at 4 ºC. The supernatant was removed, and the probe was 
allowed to air dry for 10-30 minutes. The probe was resuspended in a volume of 
hybridization buffer equal to the volume before precipitation. It was then left overnight 
on a shaker for homogenization in the dark. The pellet may still remain after the night, 
but would be easily dispensed with by gentling pipetting the solution. The probe was 
stored at -20 ºC and aliquoted when needed.  
 
The precipitated probe used per slide was optimized to 2.5-3.0 μl, diluted with a further 
10 μl of hybridization buffer per slide.   
 
2.2.2.4 Nick translation  
The second set of nested gag primers amplified the complete gag gene, which is about 
1.5 kb in size. 
 
The new probes were tested using the same protocol as before. While it detected the viral 
genetic material, it was inefficient in penetrating the cell nucleus. Thus the probe 
manufacture, and hybridization conditions were altered in parts to try and accommodate 
the entry and hybridization of the new probe (For a complete summary of the 
troubleshooting process, please see Appendix A).  
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Nick translation was the chosen method for labelling and manufacturing FISH probes 
from the second sets of gag primers. FITC was substituted for Spectrum Green – dUTP in 
this process. Dnase I, DNA polymerase I, dNTPs, Spectrum Green – dUTP, and 
appropriate buffers were incubated (see appendix I). The fragment size was checked on a 
2% agarose gel. If it was satisfactory, the probe was inactivated. Precipitation of the 
probe was in the same manner as previously described, with the additional input of 
human C0t 1 DNA.  
 
2.2.3 FISH 
2.2.3.1 Hybridization  
The slides to be hybridized were removed from the -70 ºC, allowed to thaw at room 
temperature, and then subjected to the following conditions for FISH.  
 
Denaturation of slides (70% formamide):  5 minutes @ 76 ºC 
Dehydration (70%, 90%, 100% EtOH):  3 minutes each @ RT 
Denaturation of probe:    5 minutes @ 80 ºC 
 
The slide was allowed to air dry a little before the probes were applied to the coverslip 
and placed onto the slide. 
The coverslip was sealed with rubber cement and allowed to set, then the slides were 
placed into an incubator at 37 ºC. Incubate and hybridize overnight (10-16 hours). 
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2.2.3.2 Washing 
The coverslip was removed from the slide by gentle tapping on the side and the slides 
were washed in the following: 
50% formamide     5 minutes @ 42 ºC, 3 times 
2X SSC:      5 minutes @ 42 ºC 
2X SSC + TWEEN 20:    5 minutes @ 42 ºC 
2X SSC + DAPI:     15 minutes @ RT 
2X SSC + TWEEN 20:    2 minutes @ RT 
 
The slide was allowed to air dry, and an anti-fading reagent (Vectorshield Mounting, 
Vecotr laboratories) was applied to the coverslip and then placed over the area of 
hybridization. Rubber cement was used to seal the coverslip and allowed to set. 
 
2.2.3.3 Slide Analysis 
Once the rubber cement has set, the slides were examined under the fluorescent 
microscope (Olympus). The cells were observed under 60X magnification, and 100X 
magnification. The images were also captured using the Genus imaging software 
(Applied Imaging, USA). 
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2.3 envelope gene V3 loop sequencing 
 
DNA extracted from patient blood (28) and bone marrow (6) were subjected env nested 
PCR. The first amplified regions of the env protein from V1 to V5; the nested PCR 
produce a product that is approximately 600 bp in size, spanning V3 to V5 of the env 
gene (see appendix I for primer sequence and protocol).  The fragment was visualized on 
2% agarose gel to confirm its presence before moving to the next step. Two PCR 
reactions were performed for each sample, with a forwards or reverse primer to obtain 
complementary fragments that can be combined during sequencing analysis. All the 
samples were processed in this manner.   
 
The products were put through chain termination to produce the varying lengths of 
labelled oligonucleotide chains, and then cleaned up using the sodium acetate method. 
The DNA was then placed through an ABI prism sequencer (ABI systems, USA) and the 
raw data (chromatogram) of the procedure were obtained. The data was cleaned up and 
analyzed using the Sequencher software (Gene Codes, USA). BioEdit© (obtained from 
http://www.mbio.ncsu.edu/BioEdit/bioedit.html), a sequence alignment editor, was used 
further clean up, and to convert the nucleotide sequences to amino acid.  
 
2.3.1 Phylogenetic analysis 
Coherent nucleotide and amino acid sequences were converted into FASTA (.fsa or .fas) 
format, and subjected to a number of software for the determination of the subtype as 
well as to check for any possible contamination in sequencing. The sequences were 
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initially aligned using the Clustal X software (obtained from ftp://ftp-igbmc.u-
strasbg.fr/pub/ClustalX/), and realigned to sequences from other major subtypes using 
BioEdit software. BioEdit was also used to determine the areas of ambiguity, i.e. where 
there may be a deletion or insertion in relation to the reference sequences. The 
Sequencher® sequence alignment software (Gene Codes, Michigan, USA) for the final 
cleaned up and alignment of the forward and reverse sequences. The cleaned data showed 
7 samples had insufficient areas of the forward and reverse strands complementary to 
each other. This did not allow alignment to create a coherent sequence that spanned the 
complete V3 loop. Consequently, only 11 samples produced coherent V3 loop sequences 
for analysis. 
 
The fully edited sequences were put through the MEGA version 3.0 (Kumar, Tamura, 
Nei, 2004) for phylogenetic analyses, as well as to test for cross-contamination in the 
sequencing process. Maximum parsimony neighbour joining tree with bootstrapping was 
used to create a phylogenetic relation of the samples with respect to their V3 loop 
sequence.  
 
The sequences were first tested for phylogenetic relations with a number of reference 
sequences. The references included other major subtypes from the M clade (A, B, D, G) 
as well as the sequences of two simian immunodeficiency virus (SIV) isolates from 
chimpanzees. Phylogenetic and molecular evolutionary analyses were conducted using 
MEGA version 3.1 (Kumar, Tamura, Nei 2004). Maximum parsimony neighbour joining 
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tree with bootstrapping was used to create a phylogenetic relation of the samples with 
respect to their V3 loop sequence. Bootstrapping of 250 times was also applied.  
 
2.3.2 11/25 amino acids 
2 amino acid positions of the V3 loop, 11 and 25, are useful indicator of the chemokine 
receptor usage. Amino acids with basic charges (arginine, lysine, or histidine) found at 
either of these positions increases the overall charge of the V3 loop and are indicative of 
the virus being X4-using (Cilliers et al., 2003).  
 
2.3.3 Position Specific Scoring Matrix (PSSM) 
The amino acid sequence were put through the Position Specific Scoring Matrix, an 
online program (http://ubik.microslu.washington.edu/computing/pssm/) that calculate the 
likelihood of the samples being the two phenotypes (NSI or SI), or the tendency of using 
CCR5 or CXCR4. The PSSM is derived from a profile, which is a collection of aligned 
sequences that contain the domain of interest and list the frequencies of amino acid in 
each position for the resulting protein. A log-odd score is calculated be matching the 
amino acid sequence of the sample to the profile. In the PSSM created by Mark Jensen at 
the University of Washington, the score range indicate the R5 viruses have a low value, 
dualtropic R5X4 viruses have intermediate score, and X4 viruses possess the highest 
numbers (Jensen et al., 2003).A alternative PSSM can be used calculates the score in 
terms of NSI/SI phenotype, with a similar pattern (NSI has low value score; SI has the 
high value scores). The dividing range for the sinsi scoring matrix is slightly different 
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compared to the x4r5 matrix, as the intermediate scores on the x4r5 matrix may reflect 
differently on the sinsi matrix. The only input required is the amino acid sequence in 
FASTA format. Following submission, the program would produce a table (R5X4 matrix 
or SINSI matrix) with the relevant data. 
 
2.3.4 Calculation of overall charge of V3 loop  
5 out of the 20 amino acids are basic or acidic at the physiological pH, and thus can 
influence the overall charge of the V3 loop. These are arginine (R), lysine (K),aspartic 
acid (D), glutamic acid (E), and histidine (H). The first two are positively charged (+1), 
the next two acidic amino acids are negatively charged (-1), while histidine possess a 0.5 
positive charge (although some software consider it to be +1). The overall charge of the 
loop can be calculated by taking account of the presence of all 5 of these amino acids and 
obtaining the negative or positive charge by the simple addition/subtraction. R5-using 
viruses typically possess +3 to +5 charge, whereas dualtropic and X4-using virus has +6 
to +9 net charge (Cilliers et al., 2003). The process was applied to all the samples that 
produced a coherent V3 loop sequence to calculate their charges.  
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Chapter 3: Results 
 
3.1 PCR products and labelling reaction 
 
3.1.1 Gag PCR 
The first round amplifies a 1.2 kb fragment, which could not be detected on agarose gel.  
 
The second round/nested PCR produces a fragment approximately 466 bp (dependent on 
possible mutations), which can be visualized on a 2% agarose gel containing ethidium 
bromide.   
 
 
                               Lane             1           2 
                 
Lane 1: molecular marker, 200 bp 
(sigmal-aldrich, PA, USA) 
Lane 2: HIV+ patient test sample 
 
 
 
 
 
                                                                                                                                                           
400 bp  
 
 
 
 
Figure 3.1: 2nd round product of the gag nested PCR. Lane 1 was the molecular 
marker (200 bp). Lane 2 was a HIV+ patient sample, placed between 400-600 bp.  
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3.1.2 Gag PCR II 
The second set of nested gag PCR amplifies the complete gag gene in the first round, 
which was about 2.5 kb in length, and could not be detected on agarose gel. 
 
The nested PCR gave rise to a ~1.2 kb fragment, which was visualized on a 2% agarose 
gel with ethidium bromide.  
 
          Lane                 1     2  
 
Lane 1: molecular marker, 200 bp 
(sigma-aldrich, PA, USA)  
Lane 2: HIV+ patient test sample 
1000 bp 
Figure 3.2: 2nd round product of the alternative gag nested PCR. Lane 1 was the 
molecular marker with 200 bp difference between each band. Lane 1 was a HIV+ 
patient sample 
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3.1.3 Nick Translation 
The random cutting activity of the DNase I used in nick translation meant that the second 
round product would be reduced to fragments of smaller sizes. Although there is a set 
time period (75 minutes) for nick translation, enzyme activity would vary from sample to 
sample due to DNA concentration. Therefore, it was necessary to visualize the size of the 
products on a 2% agarose gel with ethidium bromide before using them for FISH probes.  
 
  Lane          1  2     3          4 
 
Lane 1: Molecular marker, 200 bp 
(sigma-aldrich, PA, USA) 
 
Lane 2: Digested 2nd PCR product
 
Lane 3:Digested PCR product, 
requires more time for digestion 
 
Lane 4: overdigested PCR 
product 
1000 bp 
 
 
Figure 3.3: 2nd round gag products after digestion by DNase I. Lane 1 was the 
molecular marker, 200 bp difference between each band. Lanes 2-4 were digested 
samples.  
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In nick translation, the optimal size of digested DNA fragments would be between 200-
500 bp. below 200 bp, the probe would lose its specificity, and become prone to stick to 
the glass slide, rather than entering the cells. Over 500 bp, the probe becomes too big to 
efficiently gain entry into the cells.  
 
In the digestion of the nested products in figure 4.4, lane 2 was the best of the three, as 
there were minimal amount of the original fragment left, and a fairly even distribution of 
the digested fragments, producing a good range of fragments for probe labelling Lane 3 
was acceptable as there was also good distribution of the digested fragments, although the 
intensity of the original product indicate that time allowed for digestion should have been 
extended. Lane 4 was the opposite of lane 2, which showed over-digestion of the 
products, which was clearly visible with a concentration of fragments near the dye front.  
 
If the digestion was satisfactory, the remainder of the product was cleaned and 
resuspended in hybridization buffer. 4-5μl was used to hybridize one slide. 
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3.2 FISH results 
 
The HIV-gag specific probes, labelled with either FITC or spectrum-green, were applied 
to a number of variations of slides to try and produce accurate pictures of the viral 
location. The process was first tested on KC42 and U87 cell lines, before use on material 
obtain from HIV+ patients. All the patients were tested in this manner.  
 
3.2.1 Positive control: R5-using virus culture  
 
Figure 3.4: Hybridization of the FITC-labelled FISH probe to the KC42 cell line 
infected with STR5/Du179, a R5-using virus. The green dots were sites of successful 
hybridization. DAPI was used as counterstain to label the cell nuclei (100X mag.).  
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The occurrence of syncytium in the R5-virus infected cell line was a common feature, as 
the cells were free floating in the culture medium, and thus tend to congregate as 
infection progresses. Syncytia formation was especially common in the mid-late (from 5th 
day) stages of the infection in these cultures. The presence of the fluorescent signals in 
and around the cell nuclei indicates the successful hybridization of the probes to HIV 
genome. The probe used was amplified from RNA extracted from the cells of the same 
culture, using PCR labelling.   
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3.2.2 Positive control: X4R5-using virus culture  
 
Figure 3.5: Hybridization of FITC-labelled FISH probes to the U87 cell line infected 
with CM9, a R5X4 (dualtropic) virus. The green dots were points where the probe 
has successfully hybridized to the HIV. DAPI was used as counterstain to label the 
cell nuclei. The arrows indicating signals that were at different planes of focus (100X 
mag.).  
 
The R5X4 infected cell suffers cytopathic effects much faster than other of the R5 
infected cultures. Dualtropic virus is highly virulent, even compared to the R5 virus that 
is virulent compared to the typical in vivo species. Consequently, it was somewhat 
difficult to locate any significant number of intact cells in these cultures. It can be seen 
that there was a large number of signals outside the cell nuclei, which was not surprising 
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as there were a high concentration of free-floating virions in these cultures. There were 
also a number of dots that was larger size, or possessed haloes around a point. This was 
due to the fact that the environment on the glass slide was a three-dimensional one; while 
the focus on one plane, it did not exclude the signals from other depth in the same field of 
focus. Therefore these larger dots of fluorescence were also positive signals, albeit 
somewhat out of focus and look bigger than what they suppose to look like. The multiple 
signals in the nucleus also seems to indicate that there are multiple integrants, or at the 
very least, multiple infection processes involving one cell. The probe used was 
manufactured using R5-using viral RNA, using PCR labelling.  
 
The probe was shown to be specific to HIV genomic material in cell cultures, with both 
R5 and R5X4 cells. The same probe would be applied to the patient samples.  
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3.2.3 Positive control: HIV+ patient whole blood  
 
Figure 3.6: Hybridization of FITC-labelled FISH probe on a blood smear slide, 
made from fresh peripheral blood from HIV+ patient (100X mag.). 
 
A large number of signals can be seen within the nuclei. The larger spots of fluorescence 
were due to the target being on the different plane of focus. Extracellular signals were 
also observed. This is a fairly clear picture of whole blood hybridization in comparison to 
earlier efforts, involving in situ hybridization (Embretson et al., 1993). Probe was 
manufactured from R5-using virus, with PCR labelling. There is a much smaller amount 
of extracellular signals compared to previous slide, which may be due to the difference in 
viraemia of an in vitro culture, versus an in vivo environment. 
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3.2.4 Negative control:  HIV- whole blood 
 
Figure 3.7: Hybridization of FITC-labelled FISH probe on a negative control blood 
smear slide, made from HIV- whole blood (100X mag.). 
 
No presence of signals within the nuclei, and only one signal (more than likely an artefact) 
is observed outside. Probe manufactured from R5-using virus RNA, with PCR labelling. 
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3.2.5 HIV+ PBMCs after ficoll-hypaque separation 
 
Figure 3.8: Hybridization of FISH probe on a ficoll-separated lymphocyte slide, 
from HIV+ patient (100X mag.). 
 
Ficoll-hypaque separation often produced cells that have become diffused and have no 
coherent shape to the nucleus. Although signals can be detected, it was not possible to 
determine whether the viral material is in the vicinity of the nucleus through active 
transport, or the breakdown of the nuclear membrane during the separation process. 
Probe manufactured from R5-using virus RNA and PCR labelling. 
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3.2.6 HIV+ bone marrow CD4+ cells after Dynabead separation 
 
Figure 3.9: Hybridization of FISH probe, to bone marrow extract after Dynabead 
separation, from HIV+ patient (100X mag.). 
 
These cells were CD4+, as they were recovered using Dynabeads. The Dynabeads had 
been removed by DETACHaBEADs in this case. Signals were present in the nuclei as 
well as their periphery. There were also a number of signals in the inter-nuclear spaces on 
the slide. Probe manufactured from R5-using virus RNA and nick translation. 
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3.2.7 HIV+ bone marrow CD4- cells after Dynabead separation 
 
Figure 3.10: Hybridization of FISH probe, to CD4- cell from bone marrow after 
Dynabead separation, from HIV+ patient (100X mag.). 
 
This was from the same sample of HIV+ bone marrow extract as the previous page, but 
with the removal of all the cells vulnerable to HIV infection and washing, it resembles a 
negative slide. It effectively demonstrates the high standard of purity and separation 
through the use of Dynabeads. Probe manufactured from R5-using virus RNA and nick 
translation. 
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3.2.8 Quantitative data from FISH analysis 
Table 4.1: CD4 counts and amount of signals detected in the CD4+ cell population of 
FISH slides from HIV+ patients. 
Sample no. CD4 count No. of T cells (total no. 
of signals) 
No. of 
monocytes/macrophage 
(no. of signals) 
Ficoll or Dynabead 
extraction 
HIV02 138 50 (149) 0 (0) Ficoll 
HIV03 50 50 (110) 0 (0) Ficoll 
HIV15 193 50 (167) 0 (0) Ficoll 
HIV17 14 50 (216) 1 (9) Ficoll 
HIV19 14 50 (233) 0 (0) Ficoll 
HIV22 308 50 (102) 0 (0) Ficoll 
HIV24 109 50 (155) 0 (0) Ficoll 
HIV25 308 200 (411) 0 (0) Dynabead 
HIV26 109 200 (643) 0 (0) Dynabead 
HIV27 245 200 (396) 0 (0) Dynabead 
HIV28 200 200 (287) 0 (0) Dynabead 
HIV29 180 200 (752) 0 (0) Dynabead 
HIV30 230 200 (438) 0 (0) Dynabead 
HIV31 250 200 (405) 1 (12) Dynabead 
HIV32 146 200 (762) 3 (35) Dynabead 
HIV33 70 200 (795) 2 (19) Dynabead 
HIV34 300 200 (343) 0(0) Dynabead 
BMHIV1 200 200 (742) 6 (60) Dynabead 
BMHIV2 148 200 (620) 15 (102) Dynabead 
BMHIV3 173 200 (608) 11 (85) Dynabead 
BMHIV4 166 200 (729) 7 (78) Dynabead 
  
 
The table shows the amount of signals detected in the CD4+ T cell and macrophage 
population. In the earlier samples, only 50 T cells were counted as the samples were 
separated using ficoll, and that method was ineffective in the amount of T cells it retained. 
It was difficult to find any significant amount of cells on the slides, consequently only 50 
cells were counted. In the Dynabead separated samples, the yield was much higher, and 
thus a greater number of T cells could be counted.  
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With respect to the CD4+ monocytes/macrophages, these numbers does not indicate the 
number of macrophages that was present on the slides. During the analysis of the slide, 
there was no intention to specifically seek out these cells to fulfil a quota, as the 
monocytes/MDMs were known to be of a low percentage. The monocytes/MDMs 
counted here were encountered as the counting for the T cell was proceeding, and thus 
were random. The differentiation between monocytes/macrophages and T cells were 
purely based on the expression of CD4, and the size of their nuclei. Expression of CD4 
was confirmed by their recovery through the use of CD4+ Dynabeads. T cell nuclei are 
smaller and more compact compared to the larger macrophage nuclei. 
 
The number of signals on a slide from a patient who has low CD4 count was generally 
higher than those with a more encouraging CD4 count.  
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3.3 Sequencing results 
 
A nested PCR targeting the env/V3 loop was used. The 2nd round product, around 600 bp, 
has to be visualized first on a 2% agarose gel before proceeding with the sequencing 
process itself.  
 
   Lane      1        2 
 
Lane 1: Molecular marker, 200 bp 
 
Lane 2: nested product from V3 
loop PCR1000 bp 
Figure 3.11: 2nd round product used for sequencing of the V3 loop.  
 
Forward and reverse sequences of the HIV samples were obtained in the forms of ABI 
prism files and analyzed using the Sequencher software (Gene Codes Corporation, 
Michigan). Only samples with coherent forward and reverse sequence that can be 
combined, so as to produce the V3 loop sequence to resolve ambiguities, were examined.  
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3.3.1 V3 loop chromatograms 
Results from the sequencing are produced as chromatograms, a series of peaks using four 
different colours to depict for the presence of a species of nucleotide (A, G, T or C) at 
any given position.  
 
 
 
Forward strand 
 
Reverse strand - reverse complement to the forward strand 
 
Reverse strand (unmodified) 
Figure 3.12: Portions of the chromatograms from sample HIV02. The arrow 
indicates the start of complementarity between the forward and reverse strand. The 
third chromatogram is how the reverse strand looked prior to reverse 
complementarity was applied. 
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The three chromatogram sections depict the beginning of the V3 loop from one of the 
HIV+ samples. The first chromatogram is the forward strand with part of the sequence 
prior to the V3 loop. The second chromatogram is the reverse strand. Using BioEdit© to 
orientate the reverse strand and to provide the complementary nucleotide, it provided a 
strand that matched the forward sequence. This is not to say there is a perfect match at 
every position: ambiguities were resolved using Sequencher. The third chromatogram 
was the reverse sequence prior to undergoing the reverse complementarity process. 
 
 
 
 
Figure 3.13: Complete V3 loop sequence, from BMHIV01. 
 
Although a product around 600 bp in size was sequenced, the V3 loop was only a small 
section of the fragment. The V3 loop is of variable length due to deletions and insertions. 
The forward strand obtained from BMHIV01 was a good example of clean sequence, 
where there were no ambiguities in any of the nucleotide position in the V3 loop.  
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Table 4.2: The predicted amino acid sequence of patients in comparison to the 
consensus sequence of a typical HIV-1 subtype C V3 loop.  
  1    5     10     15     20     25     30     35
Consensus sequence  C T R P N N N T R K S I R I G P G Q T F Y A T G D I I G D I R Q A H C
                
HIV02  - I - - - - - - - - - V - - - - - - V - - . - D - - - - - - - - - - -
HIV03  - I - - G - - - - - - V - - - - - - A - F - - - - - V - - - - K - Y -
HIV15  - - - - - - - - - - - - - - - - - - V - - - P - - - - - - - - - - - -
HIV18  - - - - - - - - - - - V - - - - - - - - - - - - E - - - - - - K - Y -
HIV19  - - - - - - - - - - - V - - - - - - V - F - - - G - - - N - - - - - -
HIV21  - V - - - - - - - - - V - - - - - - - - - - - - - - - - N - - E - - -
HIV22  - - - - H - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
HIV24  - - - - H - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
HIVBM01  - - - - - - - - - - - - - - - - - - A - - - - - - - - - - - - - - - -
HIVBM03  - - - - - - - - - - - V - - - - - - V - - - - N - - - - N - - - - - -
HIVBM04  - V - - K - - - - R - M - - - - - - V - - - . N - - - - - - - - - - -
 
18 samples were sampled, but only 11 produced coherent forward and reverse sequences 
that combined to provide unambiguous V3 loop sequences. The combined sequences 
generated the amino acid sequences listed in the table above. 
 
The typical V3 sequence of a subtype C virus contains 35 amino acids, beginning with a 
CTRP motif, a crown GPGQ motif, and ending with a RQAHC motif.  The motifs at the 
two ends of the V3 loop are typically quite well conserved, but there are still variations 
within them. The tyrosine to valine/isoleucine substitution at the second amino acid; 
glutamine to lysine/glutamic acid substitution at position 32 and the tyrosine to histidine 
subtition at position 35 are mutation that has been observed previously, and appears to 
have no effect on V3 loop functionality (Cilliers et al., 2003). 
 
The GPGQ motif (highlighted in blue) is highly conserved in HIV, and each subtype 
posses different crown motif (Treurnicht et al., 2002; Cillier et al, 2003). There were no 
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changes at all in the region, which is consistent with existing data. The two amino acid 
positions highlighted in green are the two key positions – 11 and 25 – that have 
considerable influences on chemokine coreceptor usage. There were no changes at 
position 11, but mutation occurred at position 25 in 3 of the samples. The mutations 
detected at position 25 are not predicted to have major impact on the coreceptor usage, as 
they were not positively charged amino acids which can raise the overall charges of the 
loop.  
 
Deletions (highlighted in purple) were also found in 2 of the sample. While X4-using 
viruses have a tendency to pick up insertions (particularly at position 13), R5-using 
viruses tend to lose amino acids instead. This does not detract from their ability from 
utilizing the chemokine receptors, but also seem to have little effects on the overall 
charges of the loop.  
 
The N-linked glycosylation site starting from position 6 of the V3 loop (NNTR) was also 
examined, as glycosylation of this site is highly indicative of the virus using CCR5. This 
was observed in all the sequences obtained.  
 
 
3.4 Phylogenetic analysis 
 
The bootstrapped estimation of phylogeny produced by MEGA3 compared the sequences 
samples against a number of reference V3 sequences from other HIV-1 subtypes within 
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the M clade. The Chimpanzee SIV V3 loop was used as the outlier. The phylogenetic tree 
showed all samples were within the subtype C cluster, and no significant similarities 
except between HIV22 and 24. HIV22 and HIV24 were obtained from a husband-wife 
pair, which explains the high degree of homology between the V3 loops. 
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0.05   
Figure 3.14: Phylogenetic tree (by neighbour joining method with maximum 
parsimony applied) and contamination analysis of the sequenced samples in relation 
to a number of subtype archetypes.  
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Figure 3.15: Phylogenetic tree (by neighbout joining method with maximum 
parsimony applied) of samples specifically within the subtype C cluster. 
 
A tree using only the subtype C reference sequences to match against the sequenced 
samples. HXB2 of subtype B was used as the outlier. The bootstrap values were not 
sufficiently significant similar in any branches save the husband-wife pair. It is also not 
possible to determine if there are any similarity between the peripheral blood samples and 
bone marrow samples.  
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3.5 Prediction of chemokine coreceptor usage 
 
Three methods can be used to predict the chemokine coreceptor used to virus isolates. 
The PSSM program not only provides the value for the matrix, but also looks at the 
amino acid at position 11/25, as well as calculates the overall charge in one complete 
table. It is therefore easier to look at all three together in the matrices below.  
 
3.5.1 Position Specific Scoring Matrix (PSSM) 
 
Table: 4.3: x4r5 PSSM matrix 
name score pred x4.pct r5.pct geno pos.chg net.chg percentile
HIV22 -8.58 0 0.22 0.89 SD 7 5 0.55
HIV24 -8.58 0 0.22 0.89 SD 7 5 0.55
BMHIV1 -10.36 0 0.16 0.74 SD 6 4 0.33
HIV2 -5.18 0 0.33 0.96 SD 6 3 0.87
HIV15 -2.96 1 0.51 0.98 SG 6 4 0.63
BMHIV3 -4.15 0 0.42 0.98 SD 6 5 0.70
BMHIV4* -3.23 0 0.51 0.98 SD 7 5 -10.00
BMHIV4* -1.34 1 0.64 0.99 S- 7 5 -10.00
HIV3 -5.79 0 0.31 0.95 SD 6 4 0.88
HIV18 -5.91 0 0.29 0.95 SE 6 4 0.62
HIV19 -4.16 0 0.42 0.98 SG 6 6 0.69
HIV21 -4.53 0 0.36 0.98 SD 6 4 0.79
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score: Sequence PSSM score  
pred: 1: CXCR4 use predicted; 0: CCR5 use only predicted  
x4.pct: Percentile of score within score distribution of known X4 viruses.  
r5.pct: Percentile of score within score distribution of known R5 viruses.  
geno: Amino acid residues at V3 sites 11 and 25; basic residues (R or K) at either or both 
of these sites is predictive of CXCR4 use.  
pos.chg: Total number of positively charged (R/K/H) amino acid residues. Higher 
positive charge has been correlated with likelihood of CXCR4 use.  
net.chg: Number of positively charged (R/K/H) amino acid residues, minus number of 
negatively charged (D/E) residues.  
percentile: If this number is over .95, this sequence is most likely not a V3.  
 
 
The column ‘geno’ indicate which amino acid is present at position 11 and 25 in these 
samples. None of them possessed amino acid of positive charges, which is indicative of 
R5-using viruses. 
 
The column ‘net charge’ provided the overall positive charges for each V3 loop. All 
except HIV19 possessed +5 or less charges, which is a characteristic of R5-using viruses. 
Although HIV19 has +6 charges, it is not necessarily an indicator for X4-tropism. Taking 
into consideration of other prediction methods, and the typical value of 7 and over for 
CXCR4-using viruses, it is more likely for the virus to be R5-using.  
 
With regards to the PSSM values, the scoring by the program indicated the majority of 
the samples were more likely R5-using viruses, save for HIV15, which was closer to 
being a X4-using virus. To test the validity of this, the sequences were run through the 
SINSI matrix.  
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There exists 2 BMHIV4 as there was a deletion present near position 25. As previously 
mentioned, position 25 is of importance as it is one of the key mutation for determining 
coreceptor switch. It was also required by the matrix for scoring, and thus the program 
took that into consideration and produced results for the variations that could occur.   
 
Table 4.4: sinsi PSSM matrix 
 
Name score pred x4.pct r5.pct geno pos.chg net.chg percentile
HIV22 -13.24 0 0.00 0.04 SD 7 5 0.55
HIV24 -13.24 0 0.00 0.04 SD 7 5 0.55
BMHIV1 -12.36 0 0.00 0.16 SD 6 4 0.33
HIV2 -3.88 0 0.10 0.99 SD 6 3 0.87
HIV15 -3.02 0 0.14 0.99 SG 6 4 0.63
BMHIV3 -6.25 0 0.06 0.92 SD 6 5 0.70
BMHIV4* -5.72 0 0.07 0.94 SD 7 5 -10.00
BMHIV4* -1.37 1 0.19 0.99 S- 7 5 -10.00
HIV3 -8.44 0 0.04 0.85 SD 6 4 0.88
HIV18 -7.73 0 0.04 0.88 SE 6 4 0.62
HIV19 -5.56 0 0.07 0.95 SG 6 6 0.69
HIV21 -11.62 0 0.01 0.30 SD 6 4 0.79
 
score: Sequence PSSM score  
pred: 1: CXCR4 use predicted; 0: CCR5 use only predicted  
x4.pct: Percentile of score within score distribution of known X4 viruses.  
r5.pct: Percentile of score within score distribution of known R5 viruses.  
geno: Amino acid residues at V3 sites 11 and 25; basic residues (R or K) at either or both 
of these sites is predictive of CXCR4 use.  
pos.chg: Total number of positively charged (R/K/H) amino acid residues. Higher 
positive charge has been correlated with likelihood of CXCR4 use.  
net.chg: Number of positively charged (R/K/H) amino acid residues, minus number of 
negatively charged (D/E) residues.  
percentile: If this number is over .95, this sequence is most likely not a V3.  
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The SINSI matrix uses similar principles as the R5X4 matrix to calculate whether the 
virus is a synctium inducing virus, as opposed to a CXCR4-using virus, and so is an 
alternate form of comparison to the R5X4 matrix results.  
 
The SINSI matrix agreed with the R5X4 matrix, save for HIV15, which it now 
considered as an NSI virus. This could indicate the virus was possibly at an intermediate 
evolutionary stage, where the virus was becoming dualtropic, thus leading to the mixed 
results from the two matrices.   
 
 
Table 4.5: Manual calculation of V3 loop charge 
  1    5     10     15     20     25     30     35 Charge 
Consensus sequence  C T R P N N N T R K S I R I G P G Q T F Y A T G D I I G D I R Q A H C  
                 
HIV02  - I - - - - - - - - - V - - - - - - V - - . - D - - - - - - - - - - - +2.5 
HIV03  - I - - G - - - - - - V - - - - - - A - F - - - - - V - - - - K - Y - +4.5 
HIV15  - - - - - - - - - - - - - - - - - - V - - - P - - - - - - - - - - - - +3.5 
HIV18  - - - - - - - - - - - V - - - - - - - - - - - - E - - - - - - K - Y - +3.5 
HIV19  - - - - - - - - - - - V - - - - - - V - F - - - G - - - N - - - - - - +3.5 
HIV21  - V - - - - - - - - - V - - - - - - - - - - - - - - - - N - - E - - - +2.5 
HIV22  - - - - H - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - +4.0 
HIV24  - - - - H - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - +4.0 
HIVBM01  - - - - - - - - - - - - - - - - - - A - - - - - - - - - - - - - - - - +3.5 
HIVBM03  - - - - - - - - - - - V - - - - - - V - - - - N - - - - N - - - - - - +3.5 
HIVBM04  - V - - K - - - - R - M - - - - - - V - - - . N - - - - - - - - - - - +5.5 
 
 
The one significant caveat in the PSSM matrix result is the rounding off of the charges 
the V3 loop carries. The software considers histidine (H) residues as carrying one full 
positive charge, as oppose to 0.5 positive charge. While this makes little difference to 
most of the sequence, for V3 loops that has 5, or 5.5 positive charges, it is significant, 
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because a V3 loop that carries 5-6 positive charges, may belong to either CCR5- or 
CXCR4-using viruses. HIV19 and HIVBM04 are two samples that falls into this 
ambiguous range, both carrying 5.5 positive charges. In such a situation, overall positive 
charge for the V3 loop becomes irrelevant, and would require other data in order to make 
a reliable prediction.    
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Chapter 4: Discussion 
 
There remain many challenges to prevent and treating human immunodeficiency virus 
infections, despite over two decades of research and investigation (Fauci et al., 2005; 
Fauci, 2005). The long period of disease progression has made it difficult to assess the 
virus’ characteristics at times of infection and transmission – long term studies (5-10 
years studies) are required to obtain results correlating time of infection and disease 
progression. There is also still no satisfactory animal model that can fully mimic the 
infected human system. To resolve these problems, researchers have been working on 
producing data regarding the virus over short periods in cell cultures. This can provide a 
fairly informative representation of the life and interactions of HIV in real infections. 
This study investigates the location of the virus in late stage infection without the 
interferences of ART, or opportunistic infections like tuberculosis. More specifically, in 
this undisturbed setting, we are trying distinguish between the two CD4+ cell populations 
of macrophages and T cells, to determine where the primary sites of infection, which may 
reflect sites of active replication. 
 
 
4.1 FISH, optimization and observations 
 
The use of FISH in HIV research has been scarce, particularly as a standalone technique. 
In spite of the advantage of localizing the target without severely disrupting the cellular 
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environment, it suffers from a low sensitivity threshold. Probe sensitivity is usually 
assured by the coverage of a large expanse of the target and flanking areas. Alternatively, 
a target of small genomic length can be compensated for if it has a high copy number, 
which would ensure successful detection. Unfortunately, with the administration of ART, 
neither condition exists. HIV genome is a mere 10 kb fragment, too small to be 
efficiently hybridized. The advantage in high copy number is at the same time eliminated 
by the antiretrovirals. At best, the used of FISH as a standalone has been confined to cell 
line experiments (Cone & Schlaefer, 1997; Deichmann, Bentz & Haase., 1997; Knuchel 
et al., 2000), or used in combination with PCR or flow cytometry to compensate (Borzi et 
al., 1996; Embretson et al., 1993; Patteron et al., 1993).  
 
Although ART has been introduced to South Africa as part of the HIV/AIDS treatment 
program, there remain a large number of infected individuals that need to be examined 
and placed onto therapy. In this situation, it has been possible to obtain whole blood or 
bone marrow from ART-naïve patients, who were in the late stages of the infection, 
admitted prior to antiretroviral treatment. High copy numbers of the virus thus still exist 
in these samples, and FISH can be used for detection in this instance. It would have been 
useful to use a protocol from one of the studies mentioned above, but these 
experimentations were not well suited for this study. They were typically performed in a 
highly controlled environment, using cell lines and in vitro experimentations, and this 
was not the setting that was required here. Consequently, it was necessary to devise a 
novel FISH variation for our use.  
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4.1.1 Optimization of HIV-specific FISH 
The probe was designed to target the gag gene of the virus. It is a region of viral genome 
that is rarely mutated in all contagious variants compared to other regions (Desai et al., 
1986; Engelbrecht et al., 2001). This would ensure the detection of the virus, no matter 
which subtype or quasi-species was present. Although the template for the probe was the 
viral RNA, the probe itself was DNA. A DNA-based probe is easier to manufacture, 
handle and store, as it is more stable and not as easily degraded.  
 
The probe and the hybridization process were first tested on cell cultures, infected either 
with R5- or dualtropic HIV-1 subtype C viruses. The probe was able to hybridize to the 
virus in both cultures, and was detectable under fluorescent microscopy. The negative 
controls using the cultures without the virus showed no hybridization within or nearby 
the nucleus. A few signals were present outside the nuclei, typically at least one field 
away from any nucleus, and only present in small number (less than 10 signals per 200 
cells counted). They were therefore unlikely to be associated with the cell cytoplasm. The 
rare signals in the control cultures were likely to be artifacts, and were a good indication 
of the fact that the probe is highly specific to the HIV genome. The low number of 
signals in the negative control is expected as the target is much smaller than the typical 
size, and would invariably lead to background signals of similar sizes and intensity (Raap, 
1998).  
 
The protocol was then transferred to material from the peripheral blood. Hybridization to 
whole blood smear slides and subsequent detection was successful, although there was a 
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high degree of background observed on these slides. This was possibly due to the 
presence of other cells and components of the blood. The probes were getting trapped by 
these elements, and created false hybridization signals. The free floating virions were also 
an obstacle. Due to the limitation of the microscope when looking at a three dimensional 
environment, these signals may appear to be associating with a cell, which would distort 
the results obtained. The negative control slides made from whole blood of HIV- 
individuals, however, had minimal signals again. It was thus more probable that the cell 
free virions were the leading cause of the large number of signals outside cell nuclei in 
whole blood.  
 
It was therefore necessary to lessen the impact from the cell free virions and components 
of the blood, as well as to concentrate the white blood cells. The first attempt was by 
centrifugation, to separate the blood into fractions by mass weight. The blood would 
separate into serum, white blood cells, and red blood cells, and the leukocytes were 
extracted by pipetting. The effects of the process on the two parameters were minimal. 
The blood separated adequately, but manual pipetting still led to a fair degree of 
contamination from other blood components, and an incomplete recovery of the 
lymphocytes. Ficoll-hypaque centrifugation was then attempted. The combination of 
ficoll and centrifugal force would create a clearer differentiation between the various 
blood fractions. This concentrated the leukocytes more than the pure centrifugation of the 
whole blood. But as it still relied on manual pipetting, the method remains affected by 
incomplete recovery of leukocytes. This was also impeded by the very low concentration 
of lymphocytes in the blood of the HIV+ individuals admitted into the study. In contrast 
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to healthy HIV- controls in the same procedure, HIV+ samples rarely had sufficient 
lymphocytes to fully cover the surface area of the tube used. It was therefore extremely 
difficult to receover all the lymphocytes without drawing the neighbouring fraction as 
well. If contamination was the issue, only a small amount of lymphocytes can be drawn 
from the tube. Small number of cells makes the screening of the slide an uncomfortable 
experience, with the cells few and far in-between. There was also the problem of broken 
cells in the HIV+ samples. Few lymphocytes seemed to be able to maintain their integrity 
following the ficoll-hypaque separation, and even the negative controls suffered to some 
extent. The reason for this remains unknown, but may be due to the centrifugation 
process.  
 
Separation through centrifugation and the inherent mass difference of the blood 
components was thus insufficient. The recovered lymphocyte would also still be a 
combination of CD4+ and CD4- cells, and it would be necessary to further isolate the 
former cell population, in order to observe the interactions between those cells and the 
virus. To resolve both these problems, Dynabeads (Invitrogen) were used, which were 
polymer beads that were uniform in size, and superparamagnetic in nature. They can be 
labelled with ligands specific to the cell population that one would like to recover, or 
remove, from the biological environment. The Dynabeads used was targeting the CD4+ 
cells only, and the efficiency of the process was highly impressive. The blood that 
remained after the CD4+ cells removal, were used to make slides and subjected to FISH. 
There were no signals associating with the nuclei of the cells present on those slides. 
When FISH was performed on the CD4+ cell population, the signals were abundant in 
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both the nuclei and the intracellular spaces. The separation was also more effective as 
there were a greater concentration of intact and infected cells. There was also a small 
increase in the number of monocytes observed. The process was as effective on the bone 
marrow extracts. Under fluorescent microscopy, the only possible way to discern the 
CD4+ monocytes from T cells was through the different size of the nucleus, as no other 
cellular structures were visible. T cells have a small concentrated nucleus (a more intense 
blue circle), while the macrophages possess a larger, more diffused nuclei. The 
macrophage nucleus was typically twice the size of the T cell nucleus, and also much 
lighter in the DAPI staining – they were faint enough for the computer software to 
dismiss as background. While it was possible to count the number of signals, it was not 
possible to capture the DAPI staining for the macrophages. This is the main reason for 
the lack of infected macrophage images, as the computer analysis software was not able 
to capture the cell nuclei properly.  
 
There is an issue of visually defining the location of the signals when examining the 
labelled slides. There is no clear cut way to differentiate a true viral integrants against a 
virus that is sharing the same locality as a cell nucleus, except by moving through the 
complete plane of the slide, and determine the plane of focus (p. o. f.) for the signals and 
the cell nucleus. There is typically one clearly defined plane of focus for the cell muclei, 
and all signals detected within the DAPI-stained areas can be considered to be inside the 
nuclei. The signals would be highly concentrated dots of green if they’re in focus. As the 
plane of focus is moved, there may be other signals that come into focus while the 
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nucleus loses its visual clarity. These would be more difficult to interpret, and would rely 
on the expertise – and to some degree – the subjectivity of the person reviewing the slide.  
Therefore, becase of the different number of signals that can exists at different depth, 
dependent on the field of focus, it is not possible to objectively state the number of 
signals per cell and justify it through single frames of image capture. It may be possible 
to superimpose multiple images of one cell to obtain a full picture, but the resulting 
image would be a highly obscure one, due to effect of fluorescent signals in and out of 
focus. The number of signals obtained for cells during the process of counting, is an 
accumulation thereof, and still images cannot be expected to be fully representative of the 
environment under the microscope.  
 
 In this study, the plane of focus was not significantly shifted when quantifying the 
number of signals relating to the cell nucleus. When the shift in plane of focus has caused 
the nucleus to become indistinct on its borders, this is considered the edge of the nucleus, 
and signals that are not in focus by this point are disregarded.  
 
The fact that the hybridization environment is a three dimensional one, which can only be 
represented as a two-dimensional one on paper, also makes it slightly difficult to make 
satisfactory comparisons to other FISH-HIV papers, even if one is to disregard the 
different in probe manufacture, hybridization methods, viral subtypes, conditions used to 
culturing the infection, and so forth. But there is without a doubt that detection of the 
viral signals is greater abundance than any previously published data (Lawrence et al., 
1990; Embretson et al., 1996). Whether this is a true reflection of repeated 
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infection/supre-infection, or the way HIV-1 subtype C infection behaves in late infection, 
may be argued, as there are no other data thus far to support, or dissuade the observations 
made in this study.  
 
4.1.2 Quantitative analysis of CD4+ monocytes/macrophages and T cells 
The HIV+ slides were then analyzed quanlitatively. The CD4+ T cells were the dominant 
population detected in peripheral blood and bone marrow – less so in the latter 
environment - with the monocytes/macrophages being very few in numbers (less than 
1%). The T cells and monocytes/macrophages can be visually differentiated with the size 
of their nuclei – the former has much smaller, brightly DAPI stained nuclei, whereas the 
latter is three to four times the size of T cell nulei, and is typically faintly stained with 
DAPI. Almost all (±99%) of the viable and structurally intact T cells detected harboured 
at least 2 positive signals, and averaged 5-10 signals in each nucleus, with an upper limit 
of 40 signals detected. With regard to the macrophages/monocytes, even when 
concentrated through the use of Dynabeads, they were still a very small population in 
comparison to the T cells. In the peripheral blood, they were almost non-existent, and 
those that were detected would only be the monocytes that were in the process of 
maturation. Only in the bone marrow extract can the monocyte-derived-macrophages be 
considered fully mature. In both environments, the macrophages were approximately 1% 
of the total number of T cells present on a slide, if not less. The peripheral blood and 
bone marrow had thus presented a very small, infectable population of cells outside CD4+ 
T cells.  
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The blood and bone marrow are therefore unlikely areas where the M-tropic viruses are 
replicating. The lymph nodes would be more probable locations where there is a 
substantial number of MDMs for HIV to infect and replication under this observation. 
However, both macrophage and T cells possessed signals within their nuclei, which 
demonstrated their status as infected cells, and possibly as reservoirs. The positive 
infection of the cells cannot be disputed as the signals were observed in the nuclei. 
Although there are a number of blocks to active replication of the virus, like the absence 
of PICs and low nucleotide concentration (Bukrinsky et al., 1992; Spina et al., 1995; Han 
et al., 2004), there has been no evidence of blocks in the integration process, once the 
viral genetic material has been transported into the nuclei. If the viral cDNA can enter the 
nuclei of the infected cells, then it can be integrated. Considering the existence of points 
of blockade, which prevent the successful production of HIV virions, a pure visualization 
of the presence and location of HIV genetic material in the nucleus is therefore 
insufficient proof of replication.  
 
The macrophages detected, all possessed no less than 10 signals within their nuclei, but 
they never approached the upper limit numbers detected in the T cells. The highest 
number observed in macrophages was 29. It has been suggested that macrophages do not 
possess a block in the export of the preintegration complex that allows the transport of 
virus genome material into the nuclei as opposed to the resting T cells. They also possess 
greater kinetics which allows greater efficiency in import of materials like nucleotides 
that would be necessary in transcription. This should theoretically mean that there are 
more copies of the viral genome in the nuclei, as there were no impediments to viral entry, 
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but that was not the case. It may be possible that there is less need for the viral genetic 
material to repeatedly infiltrate the macrophage nuclei to ensure successful integration 
and replication, due to higher kinetic of the cells.  
 
In contrast, the T cells have multiple blocks to the import of the viral genome into the cell 
nuclei, as mentioned above (Bukrinsky et al., 1992; Spina et al., 1995; Han et al., 2004).  
When the blocks in the T cells are removed, the viable material that hasn’t degraded 
would be able make their way into the nucleus, and causing the large number of signals 
in the compartment. Alternatively, signals inside and near the nuclei may be describing 
the presence of new viral material. They have accumulated within the nuclei or cytoplasm 
due to the slow kinetic nature in the resting T cells and a lack of export signals.  
 
The examination of CD4- cell populations left behind by the Dynabead isolation, 
followed by FISH, also confirmed the fact that HIV-1 was not able to infiltrate these cells. 
Haemopoeitic progenitor cells in the bone marrow would fall into this group, where 
around 90% are CD34+CD38+ cells, which have a minimal expression of CCR5 on their 
surfaces. The remaining 10% are CD34+CD38- cells that have a low level of CCR5 
expression. Other CD4- cells in the bone marrow typically express CXCR4 (Berkowitz et 
al., 1998a). So even with viable chemokine coreceptors present on these cells, the virus 
actually cannot substitute CD4 with other surface receptors to gain access into cells; or at 
least, not in the peripheral blood and bone marrow tissues.  
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4.2 Phylogenetic analysis  of samples and prediction of chemokine 
coreceptor usage 
 
The incongruence between the presence of the virus in the CXCR4-expressing T cells 
and the supposed rarity of X4-using viruses in the South African HIV+ population,  
predominantly infected by HIV-1 subtype C, have posed an interesting dilemma in this 
study (Tscherning et al., 1998; Peeters et al., 1999; Morris, et al., 2001). It was therefore 
necessary to determine the chemokine coreceptor usage by the viruses in the sample 
obtained. While the relationship that exists between the switch of chemokine coreceptor 
usage from CCR5 to CXCR4, and the viral phenotype change from NSI to SI, is not an 
absolute one. The presence of the X4-using virus is a good indicator of the virus mutating 
to a SI phenotype (Dong et al., 2005). The SI virus is also typically much more 
aggressive, and leads to rapid disease progression as well as decreased survival time. In 
monitor seropositive cohorts, as well as for evaluating antiretroviral therapy trials, the 
appearance and presence of X4-using virus has been used as a marker for these two 
conditions (Richman et al., 1991; Koot et al., 1993).  
 
4.2.1 Phylogenetic analysis  
18 samples were submitted to sequencing using the ABI prism 2100 sequencer, but only 
11 samples produced coherent V3 loop sequences for analysis. Phylogenetic and 
molecular evolutiondary analyses of these samples were conducted using MEGA version 
3.1 (Kumar, Tamura, Nei 2004). 
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The software provides a number of options for the creation of phylogenetic trees, 
although in this analysis, only the neighbour-joining method was used to produce the tree. 
This method devised by Saitou and Nei (1987) construct phylogenetic trees by defining 
pairs of nearest nodes (which leads to minimal number of branches in the tree) as 
neighbours, and repeats the process until all the samples has been paired off in such a 
manner. The lengths of the tree branches were then calculated and provide a value as to 
how similar the neighbours were. It also inferred the amount of evolution and similarities 
that occurs between the samples. The advantage of the neighbour-joining method was 
that it does not assume a constant rate in the samples’ evolution, which makes it a more 
realistic model. Compared to other models of analysis that used the principle of minimum 
evolution, the neighbour-joining method is also less time consuming, uses less 
computational procedures and remains accurate in its predictions (Kumar, Tamura and 
Nei, 2004).  
 
Here, MEGA 3.1 was not only used to observe the phylogenetic relationships, but also to 
check if there was any cross contamination of samples that may have occurred during the 
sequencing process. There were no patterns of association between the samples 
themselves that suggested a possibility of contamination. There were two samples that 
were genetically identical to each other (samples HIV22 and HIV24), but this can be 
explained by the fact that they were a husband-wife pair, one of whom had transmitted 
the virus to the other. With respect to the phylogeny of the samples and the reference 
sequences, all the samples were most closely related to the subtype C reference samples. 
These were all clustered within the same branch in which the subtype C reference 
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sequence was placed. This short fragment was insufficient to produce evolutionary 
information that pertains to the virus outside of the loop, due to the lack of additional 
genetic information.  
 
Bootstrapping was also applied to the analysis, which attempts to determine probability 
distribution in the data group by randomly sampling the group. Bootstrap is a resampling 
process that quantifies uncertainties by calculating standard errors, confidence intervals, 
and significant tests (Soltis & Soltis, 2003). It has only become viable through the advent 
of computers, and in comparison to traditional resampling methods, it required fewer 
assumptions, and may provide more accurate answers. There is disagreements concerning 
at what point the bootstrap value is considered significant, but at least 95% bootstrap are 
usually considered to be significantly between neigbouring samples. There are certain 
situations, though, where 70% bootstrap proportion is deemed to correspond to a ‘real’ 
clade. In the sequenced samples, only the husband-wife pair presented significant 
correlation, which was expected in this case. Although a straightforward phylogenetic 
tree looks almost identical to its bootstrapped counterpart, save for the fact that latter 
possess values at each branch (see figure 4.1). Bootstrap is usually set between 100-1000 
resampling, and there is no consensus as to how many times resampling is optimal for a 
sample population. The sequences were resampled 250 times in this instance, which is 
theoretically sufficient for such a small sample size.  
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Figure 4.1: patient V3 loop sequence with subtype B, C and chimpanzee reference 
sequences. The first tree (by neighbour joining) is without bootstrapping, while the 
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second tree (also by neighbour joining) is bootstrapped 250 times. The values at 
each branch are the estimated genetic similarities between the neighbours.  
 
Due to the short length of the V3 loop sequence, it is again difficult to obtain significant 
data from bootstrapping. This could be remedied by sequencing more of the flanking 
region of the V3 loop; alternatively, distance matrix may be utilized to determine the 
genetic similarities between the samples. Nonetheless, there are other ways to determine 
subtypes, as will be discussed. The only disadvantage is that one cannot estimate the 
genetic similiarities between samples.  
 
4.2.2 Analysis of the V3 loop amino acid sequence 
The samples’ V3 amino acid sequence can also provide some validation to their subtypes, 
purely by visual comparison of the sequences obtained. There are three motifs that exist 
within the V3 loop that showed noticeable differences between the various subtypes, and 
they are conveniently situated at the beginning, the middle, and the end of the sequence. 
The first motif is a four amino acid sequence that denotes the start of the V3 loop, 
typically ‘CTRP’. The variations often occur at the second position, including valine (V), 
and isoleucine (I), both of which appeared in the samples, as well as alanine (A), cysteine 
(C), and tyrosine (Y). There were no variance with the first, third or fourth amino acid 
positions, and was also consistent in the reference sequences. The second motif is at 
position 15-18, and is the crown of the V3 loop. This region is less mutable than other 
regions of the loop and highly consistent. With the exception of subtype B, which almost 
always possesses a ‘GPGR’ motif, most of the other subtypes have ‘GPGQ’, with a few 
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‘GPGR’ variant and even more rarely, ‘GPGK’. All the samples had the ‘GPGQ’ 
sequence in this motif, making it more likely that they are subtype C than B, which is the 
second most frequent subtype in South Africa. The third motif at the end of the V3 loop, 
is typically a ‘RQAHC’ amino acid sequence in all the subtypes. There are many more 
variations on the end of the V3 loop compared to the other two motifs. Two variations 
that appeared in the sequenced samples were ‘RKAYC’ and ‘REAHC’; the former 
appeared in the references in more obscure subtypes like F and J, while the latter does not 
occur at all, although the individual substitutions do occur in the reference subtypes.  
 
The other region of interest in the V3 loop was from position 5-10, which typically 
carries the ‘NNNTRK’ sequence. The amino acid in position 6, which is also in this motif 
(also known as g15, as it is the 15th N-linked glycosylation position in the gp120) has 
been acknowledged as being a site of N-linked glycosylation, and this modification has 
been found to have different preferences for the chemokine coreceptors (Pollakis et al., 
2001), The lack of a glycosylated amino acid at position 6 allows more efficient use of 
the CXCR4 receptor by the protein. CCR5 functions better with a glycosylated amino 
acid (Polzer et al., 2002). The sequences were subjected to another online software that 
accounts for the number of N-linked glycosylation sites 
(http://www.hiv.lanl.gov/content/hiv-db/GLYCOSITE/glycosite.html; Zhang et al., 2004). 
It was found that all of the samples possessed a glycosylated asparagine, thus making 
them more prone to association with CCR5. So while a purely visual inspection of the 
three motifs in the V3 loop cannot provide definitive proof that a sequence belongs to a 
specific subtype, it does allow a limited comparison which narrows down the possibility 
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of the samples’ subtypes. It is also of some interest to note that the SIV reference samples 
largely maintained these motifs, and even the mutations that do occur in these regions can 
also be found in the HIV sequences (see reference sequences on NCBI CoreNucleotide: 
accession no. EF535994; AF057283; Y14359). This seems to suggest that even in the 
simian virus, these regions are quite critical in the function of the V3 loop and interaction 
with the chemokine coreceptors, and is therefore conserved.  
 
A purely visual examination of the V3 sequences also revealed the presence of single 
amino acid deletions, which had occurred in two of the samples. With the subtype C V3 
loop, mutation of this nature is very rare, but there seems to be minimal side effects from 
the loss of single residues (Batra et al., 2000; Engelbrecht et al., 2001). There are no 
specific positions where the deletion can occur, but it appears that they rarely occur 
within the motifs mentioned above. This is interesting as the SI variants have a tendency 
to gain amino acids, and typically creating a V3 loop that is 37 amino acids long. When 
such an event does occur, it is often a two amino acid insertion between position 13 and 
14 (Cilliers et al., 2003).  
 
4.2.3 Predicted chemokine coreceptor usage  
Using the 11/25 rule, the samples sequenced were all of the NSI phenotype, as there were 
no mutations at position 11, while there were only 3 samples that possessed mutations at 
position 25. These included glutamic acid (E) and glycine (G). As neither of these was 
positively charged amino acids, they made no difference in the application of this 
positional rule. There have also been comments made concerning mutation occurring at 
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position 324 of the gp160 (position 29 of the V3 loop) as also being able to influence 
viral phenotype (De Jong et al., 1992). Three samples had mutations at this position, but 
there was no such indication in them to suggest that the phenotype had changed from NSI 
to SI. However, the mutations presented were all aspartate (D) to asparagines (N), where 
the previous observations saw changes to arginine (R), which were associated with the 
phenotypic change.  
 
The samples were then subjected to both PSSM matrices. In the sinsi matrix, all the 
samples had low scores. This was indicative of the samples being non-syncytium 
inducing. Similarly in the x4r5 matrix, most of the samples also had low scores which 
leaned towards the use of CCR5 for the virus. There was one sample (HIV 15), however, 
that produced a score that tended toward an X4-using virus. But at the same time, the 
percentage of this likelihood indicated by the x4r5 PSSM was only 51% as being a X4-
user, as opposed to the 98% likelihood of it being a R5-user. Together with the value 
from the x4r5 matrix, as well as results from other analyses, the data strongly suggest that 
HIV 15 is still a NSI/R5-using virus. The final process of calculating the total charges 
present for the sample V3 loops showed that there were two samples that possessed total 
positive charges above 5 – BMHIV04 and HIV19 both possessed a charge of 5.5, which 
placed them between the two typical numerical parameters that classified the R5- and 
X4-using viruses. But as with the previous discrepancies, the samples are more likely to 
be CCR5-users, as the charges are not highly positive, and other data points them towards 
being the original phenotype that has not mutated. The PSSM had also calculated the 
total positive charges of the V3 loop of the samples, where the histidine was considered 
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as a +1 charge. This difference was reflected in the nett charges of the samples, as the 
HIV19 total charge was rounded up, whereas the BMHIV04 was rounded down. The 
difference was influenced by the overall composition of the V3 loop.  
 
Although phenotypic prediction via the V3 loop amino acid sequences is a viable, and a 
usually reliable method, it remains that there is no HIV-1 subtype C specific software to 
calculate the likelihood of the subtype C phenotype. The software used generate the 
SINSI and R5X4 matrixes uses sequence data from subtype B, which have been 
acknowledged to have quite different disease progression to subtype C. The one caveat is 
that even with a subtype C specific software, the predictions are still not guaranteed to 
match the phenotype. So while the result is a useful indicator, it is by no means correct in 
all aspects – it remains a phenotype predictor – useful for quick results, or where a 
culturing facility is not available. 
 
The bioinformatics results are strong indicators that all the sequenced samples to be 
subtype C, NSI, CCR5-users. Only 11 out of the 21 samples produced V3 loop data after 
sequencing and the subsequent analysis. The remainder of the samples may be of the 
same phenotype, although it was not possible to determine this. This supposition is made 
because subtype C is the prevalent virus in South Africa, and previous publication has 
shown HIV-1 in the region to be largely non-syncytium inducing, and utilizing CCR5 for 
entry (Abebe et al., 1999; Bjornal et al., 1997; Morris et al., 2001). Even though there is a 
high rate of mutation within the V3 loop, the data presented here has shown the mutations 
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often do not contribute to the change in chemokine co-receptor usage. This is also in line 
with previously published research (Morris et al 2001; Treunicht et al., 2002).  
 
 
4.3 Theories and hypotheses 
 
Current and past data has shown that HIV-1 subtype C predominantly utilizes CCR5 as 
their choice of chemokine coreceptor to gain entry into the viable CD4+ cells from the 
initiation of pathogenesis, and rarely changes to using CXCR4 as the disease progresses 
(Abebe et al., 1999; Peeters et al., 1999; Tien et al., 1999; Morris et al., 2001). This is in 
stark contrast to the HIV-1 subtype B infection, where around 50% of the cases do switch 
to utilize CXCR4, or both of these chemokine coreceptors (Deng et al., 1996; Feng et al., 
1996; Connor, et al., 1997). There is nothing at the present to suggest that the disease 
progression in HIV-1 subtype C undergoes the same pattern with a change chemokine 
coreceptor usage. But there remains the fact that towards the end of the infection by HIV-
1 subtype C, the CD4+ T cells are depleted in the same manner as the subtype B 
infections. This is occurring even though the majority of the cells express low or no 
CCR5, which removes the primary route of direct interaction between the virus and cells. 
Here, FISH and V3 loop sequencing of the virus from HIV+, ART-naïve patients have 
shown HIV-1 subtype C is able to infect monocytes/macrophages and T cells, in spite of 
the virus being CCR5-users. It therefore present a different scenario to those previously 
observed. 
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There are a number of possible hypothesis to explain the conundrum. The first theory 
deals with the status of the cells of the immune system in the infected individuals. The 
expression of chemokine coreceptors on these cells varies greatly in a natural, non-HIV 
infected system, as earlier described (Wu et al., 1997; Berkowitz et al., 1998; Mo et al., 
1998). The presence of HIV may well alter this, especially if the virus was striving to 
modify the cellular environment to enhance its infection and transmission capability. This 
viral intervention may have led to CCR5 being upregulated. The chronic activation of the 
immune system may have also contributed to the spread of the virus into uninfected 
CD4+ T cells. Under normal circumstances, only a very small percentage of the total T 
cell population are activated T cells, which express CCR5 in abundance (Bleul et al., 
1997; Wu et al., 1997; Berkowitz, 1998). As the immune system is constantly challenged 
by the virus and other opportunistic infections, the majority of the activated cells are 
unlikely to survive the cytopathic effects of the virus. It has been shown that the rate of 
death for these cells does exceed the turnover rate of the population (Grossman et al., 
2000). It would therefore be possible that, due to the inability of the T cells to shut down 
the infections, more and more CD4 T cells become activated. But instead of successfully 
curbing and ending the infections, the increased activation actually makes the greater 
portion of the population vulnerable to infection.  Those cells that do survive and become 
memory cells, would still maintain the integrated HIV genome. When responses from 
these cells are required and they become activated, the viral genome would then be 
expressed and new virions produced. This may explain the large number of infected cells, 
which occurred by clonal expansion of the previously infected memory T cells rather 
than individual de novo infections.  
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It may be possible that the virus was utilizing other chemokine coreceptors present on the 
T cells to gain entry into these cells, which cannot be totally dismissed as the prediction 
for chemokine coreceptor usage was only for the CCR5 and CXCR4. Having said that, 
this is a less likely scenario compared to use of other corecepors, as the use of alternative 
chemokine coreceptors has usually been rarities, only demonstrated in cultures and 
subtype B viruses (Alkhatib, et al., 1997; Alkhatib et al., 1997a; Deng et al., 1997; Farzan 
et al., 1997; Pohlmann, Krumbiegel & Kirchhoff, 1999). Even in such circumstances, the 
efficiency of the alternative chemokine coreceptors usage was weak compared to CCR5 
or CXCR4 (Zhang et al., 1998).   
 
Secondly, variants of the viral envelope protein have been demonstrated to display 
stronger binding affinity for CD4 and CCR5. This allows the virus to enter cells with 
limited numbers of these receptors (Gorry et al., 2004; Miller et al., 2001; Peeters et al., 
2003). Although this only in reference to a mechanism of CNS invasion by the virus 
where brain macrophages and microglia expresses low levels of these receptors, it is a 
possible avenue for the virus to exploit to gain entry into cells elsewhere in the body, 
where small numbers of these receptors exist, and may impose a similar limiting factor.  
 
Thirdly, HIV-1 is not as haphazard in its approach of infecting new cells as one might 
expect, purely relying on the chance that when a virion encounters a cell, that there are 
the necessary receptors that will allow the virus access. In vitro studies had indicated the 
exploitation of cell-to-cell interfaces – known as synapses -that can occur naturally 
between cells (Jolly & Sattentau, 2004). Although cells of various lineages use these 
 118
contacts to communicate with each other, only neuronal and immune system cells posses 
the ability to form synapses, where specific arrangements of molecules and structures are 
created to allow the cross talking (Taner et al., 2004). For HIV, the immunological 
synapses are of certain importance, because the cells involved are ones that the virus is 
able to infect, including dendritic cells and T cells. The synapses can form between the 
mucosal dendritic cells, which capture the virus, and transfers these still intact viruses 
through the use of multivesicular bodies (MVB) to T helper cells. This is a much more 
efficient method of transference when compared with the infection initiated by cell free 
viruses. Secondly, the T cells also create synapse between one another, which is usually 
used to facilitate transcriptional activation, or secretion of activating cytokines like 
Interleukin-5 across the synapse (Jolly & Sattentau, 2004). When this is subverted to 
allow the transmission of HIV-1, the synapse allows the rapid recruitment of CD4 and 
CXCR4 along with other components necessary for the formation of the synapse (which 
includes talin, actin, and LFA-1) at the point of contact. This promotes the budding of 
virions into the synapse cleft – spaces that form between points of contact that the cells 
have created – and then followed by the fusion of the virus to the uninfected cell 
membrane.  
 
Although such synapses have not been demonstrated in macrophages or between 
macrophages and T cells, such an event may be possible, with respect to the cell lineages 
that have been shown in vitro to form synapses (i.e. the immune system cells). It would 
thus allow the transference of viable virions from infected macrophages to uninfected T 
cells. In this scenario (transference from T cell to T cell), as well as the synapse 
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formation that occurs between mucosal dendritic cells and T cells, it would be an ideal 
situation for the virus to enter the usually invulnerable portion of the T cell population. 
Thus, the presence of the virological synapse is of certain detriment to the control of the 
viral transmission. HIV could exploit a naturally occurring event in the immune system, 
which is even more adapted at the efficient spread of the virus to uninfected cells than the 
infection initiated by free-floating viruses. Chemical communication by resting T cells 
utilizing the synapse for reactivation, may even allow infection of previously naïve 
resting T cell.  However, the occurrence of these events has yet to be shown to be a 
widely spread phenomenon and of importance in the pathogenesis of HIV-1 in vivo. 
Nonetheless, it should be seen as a possibility of virus infection and transmission that the 
virus could use if the conventional processes were severely restricted by the patient’s 
immune system.  
 
Lastly, it is possible that HIV-1 subtype C have other points of entry into CD4+CXCR4+ 
T cells aside from the mechanisms and scenarios proposed above. Many of its 
interactions and characteristics remains unclear, and it is possible that the virus is 
exploiting alternative pathways into CD4+ T cells.  HIV-1 has so far managed to thwart 
all attempts aimed at its full eradication from an infected system, so it would not be 
unexpected for the virus to possess a myriad of approaches, aside from hypothesized 
influence over chemokine coreceptor expression, subversion of cell synapses, and taking 
advantage of opportunistic infections.  
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There remains the possibility that the percentage of subtype C X4/SI isolates is not an 
accurate one. Most of the publications concerning subtype C had shown the existence of 
the SI isolate to be extremely rare, ranging from none to 6% of the sample population 
(Abebe et al., 1999; Bjornal et al., 1997; Morris et al., 2001). On the other hand, there is 
also data showing that this may be higher than expected, although only by approximately 
another 10% (Cilliers et al., 2003). In all these cases, the sample population size were no 
bigger than 50. Furthermore, the samples were also all PBMC samples, and did not 
provide any data concering the virus’ chemokine coreceptor usage in other compartments. 
This may lead to a bias in the use of CXCR4 by the virus.  
 
Therefore, the number and percentage produced may provide a good indication of the 
trends and pattern of infection, but they are no by means a comprehensive model for 
subtype C. So while it is acceptable to infer the rarity of X4/SI isolates in HIV-1 subtype 
at this point, the situation where the existence of X4/SI isolate in subtype C being the 
similar rate of occurrence as subtype B cannot be ruled out entirely. This would also 
explain the depletion of the CD4+ T cells in HIV-1 subtype C infections. Nonetheless, 
this would only apply for X4-using viruses, and certainly cannot account for the virus 
detected in this study, which has been determined to be CCR5-users. 
 
 
4.4 Other observations from the study 
 
The use of FISH to determine the sites of replication in the late stage, ART-naïve system  
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was informative to some extent. It had been previously assumed that the determinant to 
the success of active replication by the virus was predominantly based on the integration 
of the viral cDNA into the host genome. This has been shown to be incorrect, as the 
replication is actually dependent on the activation of the infected cell (Stevenson et al., 
1990, Korin & Zack, 1998; Korin & Zack, 1999). The factors that prevent active 
replication by the virus are particularly important when dealing with the issue of the 
latent reservoir, as they in part form the block that keeps the replication rate of the virus 
in check. The direct infection of resting CD4+ T cells can occur, but it usually does not 
lead to the integration of the virus. However, isolation of pure populations of resting 
CD4+ T cells in infected individuals have been found to contain low level of integrated 
DNA (Bukrinsky, et al., 1992; Chun et al., 1997). This would be possible through the 
infection of previously activated T cells, and have managed to revert to the resting state 
to be reactivated sometime in the future, as part of the immunologic memory response. 
Most of the infected T cells detected in peripheral blood would theoretically be of naïve 
phenotype, as the majority of T cells in whole blood are of that group. But as naïve T 
cells have no CCR5 expression, and only CXCR4, it means that these infected T cells 
could be memory T cells, as they do present CCR5 on the surface (Bleul et al., 1997; 
Berkowitz et al, 1998a). Alternatively, the chronic activation of the immune system may 
have led to a very low level of naïve T cells in circulation. The T cells would thus either 
be activated, or memory T cells. The latter would also become the dominant T cell 
populations in the peripheral blood (Bajaria et al., 2002).  
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Therefore, the factors that limit the latent reservoir are the same as the one that limit sites 
of active viral replication. The HIV-gag probe obviously cannot take these components 
into account, and so cannot provide a successful description of these cells. FISH is still 
able to reveal the existence of cells that has viral genetic materials within their nuclei. 
This was positively correlated with T cells of HIV+ patients, both in PBMCs, as well as in 
the bone marrow extracts. This also included the monocytes/MDMs within the two 
compartments, but these are less controversial when the chemokine coreceptor usage is 
taken into account, with them possessing the appropriate entry coreceptors already.  
 
The overwhelming presence of infected T cells suggests that the depletion may be a 
consequence of infected cell death. The main argument against direct killing mechanisms 
have been the small number of cells the virus infects, as the overwhelming majority of 
CD4+ T cells are usually inactive, and so cannot be infected by the virus. In this study, 
the virus appears to have overcome the problem. This suggests the direct interaction of 
the virus in infecting the T cells are of significant contribution to CD4+ T cell depletion.  
 
The number of signals detected in CD4+ cells in this study was also contradicted the 
experimental results obtained in early HIV studies. Viral DNA detection put the number 
of cells harbouring the virus at 1 in 100 cells (Psallidopolous et al., 1989; Schnittmann et 
al., 1989), while the expression of HIV-1 mRNA by infected cells were in one to two 
order of magnitude lower (Harper et al., 1986; Embretson et al., 1993; Embretson et al., 
1993a). The results obtained here were of several magnitudes higher. Almost all the 
viable CD4+ cells were infected, and also possessed signals in the teens. The possible 
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explanation for the vast difference could be due to the difference in the experimental 
parameters. These earlier studies were in vitro, cultured experiments, and also used 
sample that were from HAART patients. Although the variant of HIV-1 was not stated in 
these experiments, it is likely that they were all subtype B infection, as these studies were 
done in USA and/or Europe. These are quite different parameters compared to those for 
this study, and may contribute to the dissimilar results. It would be useful to resolve by 
performing the experiments in this study on early stage HIV infection samples obtain in 
South Africa.  
 
 
4.5 Future work & prospects 
 
Although FISH and the V3 loop sequence analyses provided data and information 
towards the HIV localization in late stage, ART-naïve, subtype C HIV-1+ patients, there 
are still a number of questions that need to be answered. 
 
The first concern lies within the collection of bone marrow samples. Bone marrow 
specimens are removed from the body via spinal puncture, which is a procedure that taps 
into the subarachnoid space between the lumbar regions of the vertebrae to obtain 
marrow material. The procedure is not performed upon the patient unless it is absolutely 
necessary, and the samples obtained from this procedure are used for morphological tests, 
like those for lymphomas. Consequently, the samples obtained in these cases, while they 
are HIV+, also possess other anomalies in the bone marrow, which can distort the picture 
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presented on the slide. Although these anomalies were not observed on the slides in this 
study, it is unknown what effects they have on the cells and cellular environment. A 
purely HIV+ bone marrow biopsy without the occurrences of marrow-related 
abnormalities would be useful to obtain and to be examined. But such samples would be 
unethical to obtain. The same principle applies with obtaining any other types of biopsies, 
as such invasive procedures are not done lightly, and only goes ahead because the tissues 
in question are diseased and a direct examination is necessary. Although there was no 
follow up on the bone marrow samples obtained whether they are confirmed lymphoma 
cases, the samples were taken because there were causes to suspect cancer. This situation 
is an unfortunate one, as it would be of great use to observe what interaction occurs 
between the virus infection in a normal, healthy bone marrow, or any other tissues that 
can be affected by the HIV-1 infection. All the bone marrow samples in this study were 
obtained as there was a need for a biopsy of the tissue. Although they were all AIDS-
related lymphoma cases, it does not detract from the possibility the cancers may have 
influenced the pattern of infection, transmission, and integration of HIV-1 in the bone 
marrow.  
 
With respect to FISH itself, one of the problems in the analysis is the lack of delineation 
between the cell cytoplasm and the intercellular spaces. Nuclei of the cells examined 
were positively labeled through the use of DAPI, and was the only cellular component 
visible under fluorescent microscopy. The visualization of coherent nuclei is a reliable 
way of detecting intact cells. Detection of signals showed that they were predominantly 
located within, or on the periphery of the nuclei. But there were also stray signals that 
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were situated in the void between the cell nuclei. Some were sufficiently close to the cell 
nuclei to be considered as being within a cell. But this is obviously quite subjective. An 
additional stain to define the cell cytoplasm would thus be of some importance when 
deciding whether the extra-nucleic signals are associated with the cells or not. Secondly, 
while the nucleus-associated signals are clearly distinguishable, the fact that the nucleus 
is a three-dimensional structure, makes it sometimes difficult to differentiate and count 
the individual signals. The analysis should therefore benefit from the use of confocal 
microscopy that can easily produce layered images of the nucleus, and make it easier to 
account for the signals. Thirdly, there is no specific association of the signals with the 
nucleic components. That is, although it is visible and fairly obvious that the signals are 
inside the nucleus, the cellular compartment remains one amorphous mass of genetic 
material. It would be highly interesting to see if the signals are integrated into specific 
chromosomes, or area of the chromosomes with which the virus is predisposed to 
associate. This could be achieved by culturing infected PBMC and induce the cells into 
mitosis, and block them in the metaphase stage where the individual chromosomes can be 
visualized. HIV-gag probes could then be hybridized to the metaphase spreads.  
 
These possible improvements do not actually subtract from the fact that the HIV-gag 
probe and the accompanying protocol was a success in detecting the presence of the viral 
genetic material. The hybridization can be adapted to be used on the other HIV-infected 
tissues, such as HIV-related lymphoma, or forms of biopsies, that still possess fairly 
intact nucleic acid species.  
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Conclusion 
 
We utilized FISH and sequencing to determine the cells that host HIV-1 in late infection, 
i.e. CD4+ monocytes/MDMs, and/or CD4+ T cells. Using FISH, we were able to observe 
the location of the viral genetic material in a minimally disrupted cellular environment. 
The V3 loop sequences and their input into a number of computational programs 
predicted chemokine coreceptor usage, virus subtype, and several other sequence based 
observations. The combined results revealed that in late stage, ART-naïve and OI-free 
infections, HIV-1 subtype C remains a R5/NSI using virus. The virus was found in CD4+ 
cells in both whole blood and bone marrow. This was regardless of the assumed 
chemokine coreceptor expression, where monoocytes/macrophages preferentially express 
CCR5, as opposed to CXCR4 on the majority of T cells. Therefore, there is a discrepancy 
with the HIV-1 subtype C chemokine coreceptor usage, and the presence of viral genetic 
material in the nuclei of T cells. 
 
We suggest several scenarios where HIV-1 subtype C may gain access into the T cells. 
Firstly, a change in CCR5 expression patterns, which may occur through viral pressure, 
or responses to suppression of opportunistic infections, is possible. The viral synapse, 
which is a subversion of the cell synapses used for cell communication and crosstalking, 
is also a possible route exploited by the virus. A sample population skewed due in the 
collection process would have contributed to the presence of virus in CD4+ T cells 
without the appropriate chemokine coreceptor. However, this remains an unlikely 
explanation. The use of other chemokine receptors outside of CCR5 and CXCR4, may 
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also contribute to this. Additionally, there could be other, yet unknown pathways that 
HIV-1 is using to circumvent the limiting factor of chemokine coreceptor.  
 
Regardless of how the virus enters the CD4+ T cells, the fact remains that in HIV-1 
subtype C infections, CD4+ monocytes/MDMs and T cells exists with HIV-specific 
genomic material. This poses the same obstacles in the treatment of the disease as with 
HIV-1 subtype B. Even though the virus was present in CD4+ cells, little else is known 
about their status and degree of interaction with the virus. For example, what chemokine 
receptors the infected cells were expressing in high concentrations; whether the infected 
T cells are naïve or memory cells; are the aforementioned cells in a resting or activated 
state; where in the chromosomes is the HIV genetic material integrated. Data on these 
questions would provide a better picture of what was occurring in these infected cells, 
and at present, work has begun on some of these aspects in order to produce data.  
 
To summarize: FISH can be a useful tool in HIV/AIDS research, and while it is not a 
method that can provide fully satisfactory answer on its own, it can be highly informative 
in conjunction with other molecular techniques. V3 loop sequencing and subsequent data 
analysis using multiple programs is also reliable, and can provide additional description 
of the region. With respect to the results, the viral presence within all CD4+ cells with 
confirmed usage of CCR5 and not CXCR4 poses an interesting dilemma. This requires a 
more detailed look into the virus-cell interaction; although this should probably take 
place in vivo, as to our knowledge, there are no hypothesis that has come out of in vitro 
experiments that can explain the contradicting phenomena.  
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We have shown the HIV-1 subtype C virus to be a persistent entity, able to infect cells 
without a direct route of infection. However, parts of the viral interaction remain unclear, 
and in-depth experimentations will be necessary to understanding these aspects. 
Knowledge of these issues will be important for the ultimate result of dealing with the 
disease, which has become a worldwide endemic.  
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Appendices 
 
Appendix I: Experimental protocols 
 
I.i. PCR/RT-PCR 
I.i.i. HIV-1 Gag amplification 
H1G777 (1st round)  5’ – tca cct aga act ttg aat gca tgg g – 3’ 
H1P202 (1st round) 5’ – cta ata ctg tat cat ctg ctc ctg t – 3’  
H1Gag1584 (nested) 5’ – aaa gat gga taa tcc tgg g – 3’ 
g17 (nested)  5’ – tcc aca ttt cca aca gcc ctt ttt – 3’  
 
 
1st round 
 1X reaction  
H1G777 (10 pmol/μl) 1.00 μl 
H1P202 (10 pmol/μl) 1.00 μl 
dNTP (10 mM) 10.0 μl 
MgCl2 (25 mM) 3.00 μl 
10X buffer 5.00 μl 
Taq polymerase 0.25 μl 
AMV RT 0.20 μl 
Sabax Water 27.5 μl 
RNA 2.00 μl 
Total 50.0μl 
 
94 ºC  5 min 
31 cycles : 94 ºC  1 min 
55 ºC  45 sec  
 153
72 ºC  90 sec 
72 ºC  10 min  
4 ºC  ∞ 
Alternatively: 
 
1st round (Using Qiagen 1-step kit) 
 1X reaction  
H1G777 (10 pmol/μl) 2.00 μl 
H1P202 (10 pmol/μl) 2.00 μl 
dNTP (10 mM) 0.80 μl 
5X buffer 4.00 μl 
RT 0.80 μl 
Sabax Water 8.40 μl 
RNA 2.00 μl 
Total 20.0 μl 
 
50 ºC  30 min 
94 ºC   15 min 
31 cycles : 94 ºC  1 min 
55 ºC  45 sec  
72 ºC  90 sec 
72 ºC  10 min  
4 ºC  ∞ 
Do not place in to thermocycler until the temperature has reached 50 ºC. 
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2nd round 
 1X 
H1Gag1584 (10 pmol/μl) 1.00 μl 
G17 (10 pmol/μl) 1.00 μl 
dNTP (10 mM) 1.00 μl 
MgCl2 (25 mM) 2.50 μl 
10X buffer 2.50 μl 
Taq polymerase 0.25 μl 
Sabax Water 13.75 μl 
DNA (undiluted) 3.00 μl 
Total 25.0 μl 
  
94 ºC  5 min 
31 cycles : 94 ºC  1 min 
55 ºC  45 sec  
72 ºC  90 sec 
72 ºC  10 min  
4 ºC  ∞ 
 
3-5 μl of the product are run on 2% agarose gel at 100 V for 40 minutes, and examined 
under UV light for the product. The product is ~460 bp.  
 
I.i.i.a HIV-1 Gag amplification, 2nd primer set 
Primer sequences:  
gag A – IP protected 
gag B – IP protected 
gag C – IP protected 
gag D - IP protected 
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1st round (Using Qiagen 1-step kit) 
 1X reaction  
Gag A (25 poml/µl) 2.00 μl 
Gag B (25 poml/µl) 2.00 μl 
dNTP (10 mM) 0.80 μl 
5X buffer 4.00 μl 
RT 0.80 μl 
Sabax Water 8.40 μl 
RNA 2.00 μl 
Total 20.0 μl 
 
50 ºC  30 min 
94 ºC   15 min 
30 cycles : 94 ºC  15sec 
55 ºC  30 sec  
72 ºC  3 min 
72 ºC  10 min  
4 ºC  ∞ 
 
2nd round 
 1X 
Gag C (25 pmol/μl) 2.50 μl 
Gag D (25 pmol/μl) 2.50 μl 
dNTP (1 mM) 8.00 μl 
MgCl2 (25 mM) 4.00 μl 
10X buffer 5.00 μl 
Taq polymerase 0.30 μl 
Sabax Water 24.7 μl 
DNA (undiluted) 3.00 μl 
Total 50.0 μl 
 
94 ºC   3 min 
30 cycles : 94 ºC  30sec 
55 ºC  45 sec  
72 ºC  3 min 
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72 ºC  10 min  
4 ºC  ∞ 
 
3-5 μl of the product are run on 2% agarose gel at 100V for 40 minutes, and examined 
under UV light for the product. The fragment is ~1.2 kb in size.  
 
I.i.ii. HIV-1 Env/V3 loop amplification  
Primer sequences:  
ED5 (1st round) 5’ – atg gga tca aag cct aaa gcc atg tg – 3’ 
ED12 (1st round) 5’ – agt gct tcc tgc tgc tcc caa gaa ccc aag – 3’ 
ES7 (nested)  5’ – ccc gcc tgt tra atg gya gyc tag c – 3’ 
ES8 (nested)  5’ – gcc gcc ata att cay ttc tcc aat tg – 3’ 
 
1st round (DNA) 
 1X reaction 
ED5 (10 pmol/μl) 1.00 μl 
ED12 (10 pmol/μl) 1.00 μl 
dNTP (10 mM) 0.80 μl 
MgCl2 (25 mM) 2.80 μl 
10X buffer 5.00 μl 
Taq polymerase 0.125 μl 
Sabax Water 38.875 μl 
DNA 5.00 μl 
Total 50.0 μl 
 
94 ºC  5 min 
31 cycles : 94 ºC  1 min 
55 ºC  45 sec  
72 ºC  90 sec 
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72 ºC  10 min  
4 ºC  ∞ 
 
 
2nd round 
 1X reaction 
ES7 (10 pmol/μl) 1.00 μl 
ES8 (10 pmol/μl) 1.00 μl 
dNTP (10 mM) 0.80 μl 
MgCl2 (25 mM) 2.80 μl 
10X buffer 5.00 μl 
Taq polymerase 0.25 μl 
Sabax Water 36.15 μl 
DNA 3.00 μl 
Total 50.0 μl 
 
94 ºC  5 min 
31 cycles : 94 ºC  1 min 
55 ºC  45 sec  
72 ºC  90 sec 
72 ºC  10 min  
4 ºC  ∞ 
 
3-5μl of the product are run on 2% agarose gel at 100V for 40 minutes, and examined 
under UV light for the product. The fragment is ~600 bp. 
 
I.i.iii. PCR labelling 
The 1st round amplification occurs as usual, and the nested following is almost the same, 
save the addition of fluorochromes to the master mix. The volume of water was adjusted 
accordingly.  
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2nd round 
 1X 
H1Gag1584 (10 pmol/μl) 1.00 μl 
G17 (10 pmol/μl) 1.00 μl 
dNTP (10 mM) 1.00 μl 
MgCl2 (25 mM) 2.50 μl 
10X buffer 2.50 μl 
Taq polymerase 0.25 μl 
Sabax Water 12.15-11.95μl 
FITC 0.6-0.8μl 
DNA 4.00 μl 
Total 25.0 μl 
 
94 ºC  5 min 
31 cycles : 94 ºC  1 min 
55 ºC  45 sec  
72 ºC  90 sec 
72 ºC  10 min  
4 ºC  ∞ 
 
I.i.iv. PCR for V3 loop sequencing 
2nd round product from the env/V3 loop nested PCR was used. Both strands of the area to 
be sequenced were amplified separately before sequencing.  
 
 1X 
ES7 (1.5 pmol/μl) OR 2.00 μl 
ES8 (1.5 pmol/μl)  
5X sequencing buffer 2.00 μl 
Sabax water 10.0 μl 
DNA  2.00 μl 
Ready reaction mix 4.00 μl 
 
25 cycles : 96 ºC  10 sec 
50 ºC  5 sec  
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60 ºC  4 min 
4 ºC  ∞ 
 
I.i.v. Pre-sequencing clean up 
Add 90 μl 100% ethanol and 10 μl sodium acetate to the amplified products. 
Spin at 2000x g for 30 minutes at 4 ºC. 
Remove the supernatant by spinning upside down at 150x g for 1 minute at 4 ºC.  
Add 100 μl 70% ethanol and spin again at 150x g for 5 minutes at 4 ºC.  
Place at 65 ºC for 5 minutes to remove any residual liquid. 
Store at 4 ºC until sequencing.  
 
I.i.vi. Nick translation 
 
 
 1X 
DNA (from 2nd round, undiluted)  20.0 μl 
Nick translation buffer 10.0 μl 
Β-mercaptoethanol  10.0 μl 
Nucleotide/spectrum mix (see below) 8.00 µl 
DNA polymerase 3.00 μl 
Dnase I (see below)  1.00 μl 
Distilled water   48.0 µl 
Total  100 µl 
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dNTP mix 
 1X 
dATP (10 mM)  1.50 μl 
dCTP (10 mM)  1.50 μl 
dGTP (10 mM)  1.50 μl 
dTTP (10 mM)  0.75 µl 
Spectrum green-dUTP 7.50 μl 
Distilled Water 1.00 μl 
Total  30.0 µl 
 
15 ºC  30 sec 
15 ºC  75min 
4 ºC  ∞ 
 
Dnase I 
Dilute 0.4 µl of stock Dnase I with 999.6 µl of sabax water. Use 1µl for every 20 µl of 
product to be digested.  
 
I.i.vii. Probe precipitation/cleanup 
For FITC PCR labelling 
Add 1/10th volume of sodium acetate and 2.5x volume of ice cold 100% ethanol to the 
PCR product. Leave at -70 ºC for 20 minutes. 
Spin at 13 000x g for 30 minutes at 4 ºC.  
Remove supernatant and add 100 μl of ice cold 70% ethanol. 
Spin at 15 000x g for 10 minutes at 4 ºC. 
Dry the pellet and resuspend in the same volume of hybridization buffer as the PCR 
product before probe precipitation began.  
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There’s also a variation of precipitating the probes for the spectrum green nick translation 
which requires the inactivation of enzymes to stop further activity.  
For spectrum green nick translation: 
After nick translation, 10 μl (denatured at 96 ºC for 3 minutes) was allowed to run on a 
2% agarose gel to check the degree of digestion. The remainder of the digested/labelled 
product was kept at -20 ºC. If the digestion was acceptable, the probes can be inactivated 
completely and precipitated. If more time for digestion is required, the product can be 
taken from -20 ºC and further digested.  
Incubate the 90 μl product at 65 ºC for 10 minutes after adding 3 μl of 0.5M EDTA, and 
1 μl 10% SDS.  
Add 90 μl C0t 1 DNA (undiluted), 1/10th volume of sodium acetate, and 2.5x volume of 
ice cold 100% ethanol. Leave at -70 ºC for 30 minutes.  
Spin at 13 000x g for 30 minutes at 4 ºC. Pour off the supernatant and add 100 μl of ice 
cold 70% ethanol.  
Spin at 15 000x g for 10 minutes. Remove supernatant and air dry.  
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Appendix II: Reagents 
 
 
II.i.  Eletrophoresis reagents 
 
II.i.i. Ethylenediamine tetra-acetic acid (0.5M EDTA) 
Dissolve 9.3 g Na2EDTA in 40ml of distilled water. pH to 8 with NaOH. When it has 
completely dissolved, make up to 50 ml with water and autoclave. Store at room 
temperature. 
 
II.i.ii. Ethidium bromide (EtBr, 10mg/ml) 
Dissolve 100 mg ethidium bromide in 10 ml distilled water. Leave on stirrer overnight. 
Filter and store at 4 °C in the dark.  
 
II.i.iii. 1X TAE buffer 
Dissolve 40 mM Tris base (hydroxymethylaminomethane), 20 mM CH3COONa.3H2O, 
and 1 mM EDTA. pH to 7.2 and make up to 1 L with distilled water. Autoclave and store 
at room temperature.  
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II.i.iii. 2% agarose gel 
Dissolve 0.6 g of agarose in 30 ml of 1X TAE buffer. Heat until agarose has dissolved. 
Add 1.5 µl EtBr. Pour into template and allowed to set.   
 
 
II.ii. FISH reagents 
II.ii.i. Phosphate buffer 
Solution A: KH2PO4. 4.54g/500 ml (pH 4.51) 
Solution B: Na2PO4.2H2O. 5.94/500 ml (pH 8.97) 
41.3 ml solution A + 58.7 ml solution B for 100ml phosphate buffer stock solution. 
 
II.ii.ii. 20X SSC (stock solution) 
175 g sodium chloride (NaCl) 
88.23 g tri-sodium citrate  
Dissolve in 900 ml of distilled water. pH to 7, and make up to 1000 ml with distilled 
water.  
Autoclave and store at room temperature.  
 
II.ii.iii. Deionized filtered formamide 
Add 1 full spatula of analytical grade mixed bed resin for every 100 ml of formamide.  
Place on magnetic stirrer for 2 hours. Filter with Whatman No. 1 filter paper. 
Store at 4 °C. 
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 II.ii.iv. Fixative 
Add 1 part acetic acid to 3 parts methanol. Use on same day.  
 
II.ii.v. Ethanol series 
70% ethanol: 7 parts ethanol plus 3 parts distilled water. 
90% ethanol: 9 parts ethanol plus 1 part distilled water. 
100% ethanol: use straight from stock bottle.  
Store at room temperature, or -20 °C.  
 
II.ii.vi. Hybridization buffer 
50% deionized formamide 
2X SSC 
10% dextran sulphate 
50mM sodium dihydrogen orthophosphate 
Adjust pH to 7 with dihydrogen orthophosphate 
 
For 25 ml of hybridization buffer: 
12 ml 50% deionized formamide 
2.5 ml 20X SSC 
2.5 g detran sulphate 
0.195 g sodium dihydrogen orthophosphate 
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II.ii.vii. Denaturing solution 
35 ml deionized filtered formamide 
5 ml phosphate buffer 
5 ml 20X SSC 
5 ml dH2O 
Adjust pH to 7 with HCl. 
Can be used for hybridization of 10 slides, or be kept for up to a week at 4 ْ C. 
 
II.ii.viii. 50% formamide washing solution 
15 ml 20X SSC 
65 ml dH2O 
70 ml formamide 
Adjust pH to 7 with HCl. 
Place 50 ml into 3 different coplin jars for washing. 
 
II.ii.ix. 2X SSC solution 
 5 ml of 20X SSC solution plus 45 ml distilled water.  
 
II.ii.x. TWEEN solution 
5 ml of 20X SSC solution plus 45 ml distilled water. Add 25 µl of TWEEN-20 and mix 
well. 
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II.ii.xi. DAPI solution 
5 ml of 20X SSC solution plus 45 ml distilled water. Add 50 µl of DAPI and mix well. 
Keep solution out of light.  
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Appendix III: Miscellaneous 
 
III.i. Conversion table: molar to moles 
 
1 Molar (M) = 1 mole/1000 ml 
1 mM = 0.001 mole/1000 ml 
0.001 mole/1000 ml = 1 mmole/1000 ml 
1 mM = 1 µmole/ml 
1 µmole/ml = 0.001µmole/µl 
1 mM = 1 nmole/µl 
1 µM = 1 ρmole/µl 
100 µM = 100 ρmole/µl 
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Appendix IV: Ethical clearance 
 
Ethical clearance was covered under the University of Witwatersrand committee for 
research on human subject (medical) protocol number M961129. 
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